Single-blinded, stratified, dose ranging trial to assess pharmacokinetics and identify optimal dose of vitamin B12 in pregnancy in Tanzania

Single-blinded, stratified, dose ranging... | Gates Open Research "use strict";function _typeof(t){return(_typeof="function"==typeof Symbol&&"symbol"==typeof Symbol.iterator?function(t){return typeof t}:function(t){return t&&"function"==typeof Symbol&&t.constructor===Symbol&&t!==Symbol.prototype?"symbol":typeof t})(t)}!function(){var t=function(){var t,e,o=[],n=window,r=n;for(;r;){try{if(r.frames.__tcfapiLocator){t=r;break}}catch(t){}if(r===n.top)break;r=r.parent}t||(!function t(){var e=n.document,o=!!n.frames.__tcfapiLocator;if(!o)if(e.body){var r=e.createElement("iframe");r.style.cssText="display:none",r.name="__tcfapiLocator",e.body.appendChild(r)}else setTimeout(t,5);return!o}(),n.__tcfapi=function(){for(var t=arguments.length,n=new Array(t),r=0;r 3&&2===parseInt(n[1],10)&&"boolean"==typeof n[3]&&(e=n[3],"function"==typeof n[2]&&n[2]("set",!0)):"ping"===n[0]?"function"==typeof n[2]&&n[2]({gdprApplies:e,cmpLoaded:!1,cmpStatus:"stub"}):o.push(n)},n.addEventListener("message",(function(t){var e="string"==typeof t.data,o={};if(e)try{o=JSON.parse(t.data)}catch(t){}else o=t.data;var n="object"===_typeof(o)&&null!==o?o.__tcfapiCall:null;n&&window.__tcfapi(n.command,n.version,(function(o,r){var a={__tcfapiReturn:{returnValue:o,success:r,callId:n.callId}};t&&t.source&&t.source.postMessage&&t.source.postMessage(e?JSON.stringify(a):a,"*")}),n.parameter)}),!1))};"undefined"!=typeof module?module.exports=t:t()}(); dataLayer = dataLayer || []; // Standard GTM initialization - Google Consent Mode handles consent automatically (function(w,d,s,l,i){w[l]=w[l]||[];w[l].push({'gtm.start': new Date().getTime(),event:'gtm.js'});var f=d.getElementsByTagName(s)[0], j=d.createElement(s),dl=l!='dataLayer'?'&l='+l:'';j.async=true;j.src= 'https://www.googletagmanager.com/gtm.js?id='+i+dl+ '>m_auth=hzk0Vc3qFsQYhCrIoHz68A>m_preview=env-1>m_cookies_win=x';f.parentNode.insertBefore(j,f); })(window,document,'script','dataLayer','GTM-MWFK8L5J'); ;window.NREUM||(NREUM={});NREUM.init={distributed_tracing:{enabled:true},privacy:{cookies_enabled:true},ajax:{deny_list:["bam.nr-data.net"]}}; ;NREUM.loader_config={accountID:"438030",trustKey:"438030",agentID:"772317073",licenseKey:"97f8f67f26",applicationID:"772317073"} ;NREUM.info={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net",licenseKey:"97f8f67f26",applicationID:"772317073",sa:1} ;/*! For license information please see nr-loader-spa-1.236.0.min.js.LICENSE.txt */ (()=>{"use strict";var e,t,r={5763:(e,t,r)=>{r.d(t,{P_:()=>l,Mt:()=>g,C5:()=>s,DL:()=>v,OP:()=>T,lF:()=>D,Yu:()=>y,Dg:()=>h,CX:()=>c,GE:()=>b,sU:()=>_});var n=r(8632),i=r(9567);const o={beacon:n.ce.beacon,errorBeacon:n.ce.errorBeacon,licenseKey:void 0,applicationID:void 0,sa:void 0,queueTime:void 0,applicationTime:void 0,ttGuid:void 0,user:void 0,account:void 0,product:void 0,extra:void 0,jsAttributes:{},userAttributes:void 0,atts:void 0,transactionName:void 0,tNamePlain:void 0},a={};function s(e){if(!e)throw new Error("All info objects require an agent identifier!");if(!a[e])throw new Error("Info for ".concat(e," was never set"));return a[e]}function c(e,t){if(!e)throw new Error("All info objects require an agent identifier!");a[e]=(0,i.D)(t,o),(0,n.Qy)(e,a[e],"info")}var u=r(7056);const d=()=>{const e={blockSelector:"[data-nr-block]",maskInputOptions:{password:!0}};return{allow_bfcache:!0,privacy:{cookies_enabled:!0},ajax:{deny_list:void 0,enabled:!0,harvestTimeSeconds:10},distributed_tracing:{enabled:void 0,exclude_newrelic_header:void 0,cors_use_newrelic_header:void 0,cors_use_tracecontext_headers:void 0,allowed_origins:void 0},session:{domain:void 0,expiresMs:u.oD,inactiveMs:u.Hb},ssl:void 0,obfuscate:void 0,jserrors:{enabled:!0,harvestTimeSeconds:10},metrics:{enabled:!0},page_action:{enabled:!0,harvestTimeSeconds:30},page_view_event:{enabled:!0},page_view_timing:{enabled:!0,harvestTimeSeconds:30,long_task:!1},session_trace:{enabled:!0,harvestTimeSeconds:10},harvest:{tooManyRequestsDelay:60},session_replay:{enabled:!1,harvestTimeSeconds:60,sampleRate:.1,errorSampleRate:.1,maskTextSelector:"*",maskAllInputs:!0,get blockClass(){return"nr-block"},get ignoreClass(){return"nr-ignore"},get maskTextClass(){return"nr-mask"},get blockSelector(){return e.blockSelector},set blockSelector(t){e.blockSelector+=",".concat(t)},get maskInputOptions(){return e.maskInputOptions},set maskInputOptions(t){e.maskInputOptions={...t,password:!0}}},spa:{enabled:!0,harvestTimeSeconds:10}}},f={};function l(e){if(!e)throw new Error("All configuration objects require an agent identifier!");if(!f[e])throw new Error("Configuration for ".concat(e," was never set"));return f[e]}function h(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");f[e]=(0,i.D)(t,d()),(0,n.Qy)(e,f[e],"config")}function g(e,t){if(!e)throw new Error("All configuration objects require an agent identifier!");var r=l(e);if(r){for(var n=t.split("."),i=0;i {r.d(t,{D:()=>i});var n=r(50);function i(e,t){try{if(!e||"object"!=typeof e)return(0,n.Z)("Setting a Configurable requires an object as input");if(!t||"object"!=typeof t)return(0,n.Z)("Setting a Configurable requires a model to set its initial properties");const r=Object.create(Object.getPrototypeOf(t),Object.getOwnPropertyDescriptors(t)),o=0===Object.keys(r).length?e:r;for(let a in o)if(void 0!==e[a])try{"object"==typeof e[a]&&"object"==typeof t[a]?r[a]=i(e[a],t[a]):r[a]=e[a]}catch(e){(0,n.Z)("An error occurred while setting a property of a Configurable",e)}return r}catch(e){(0,n.Z)("An error occured while setting a Configurable",e)}}},6818:(e,t,r)=>{r.d(t,{Re:()=>i,gF:()=>o,q4:()=>n});const n="1.236.0",i="PROD",o="CDN"},385:(e,t,r)=>{r.d(t,{FN:()=>a,IF:()=>u,Nk:()=>f,Tt:()=>s,_A:()=>o,il:()=>n,pL:()=>c,v6:()=>i,w1:()=>d});const n="undefined"!=typeof window&&!!window.document,i="undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self.navigator instanceof WorkerNavigator||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis.navigator instanceof WorkerNavigator),o=n?window:"undefined"!=typeof WorkerGlobalScope&&("undefined"!=typeof self&&self instanceof WorkerGlobalScope&&self||"undefined"!=typeof globalThis&&globalThis instanceof WorkerGlobalScope&&globalThis),a=""+o?.location,s=/iPad|iPhone|iPod/.test(navigator.userAgent),c=s&&"undefined"==typeof SharedWorker,u=(()=>{const e=navigator.userAgent.match(/Firefox[/\s](\d+\.\d+)/);return Array.isArray(e)&&e.length>=2?+e[1]:0})(),d=Boolean(n&&window.document.documentMode),f=!!navigator.sendBeacon},1117:(e,t,r)=>{r.d(t,{w:()=>o});var n=r(50);const i={agentIdentifier:"",ee:void 0};class o{constructor(e){try{if("object"!=typeof e)return(0,n.Z)("shared context requires an object as input");this.sharedContext={},Object.assign(this.sharedContext,i),Object.entries(e).forEach((e=>{let[t,r]=e;Object.keys(i).includes(t)&&(this.sharedContext[t]=r)}))}catch(e){(0,n.Z)("An error occured while setting SharedContext",e)}}}},8e3:(e,t,r)=>{r.d(t,{L:()=>d,R:()=>c});var n=r(2177),i=r(1284),o=r(4322),a=r(3325);const s={};function c(e,t){const r={staged:!1,priority:a.p[t]||0};u(e),s[e].get(t)||s[e].set(t,r)}function u(e){e&&(s[e]||(s[e]=new Map))}function d(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:"",t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:"feature";if(u(e),!e||!s[e].get(t))return a(t);s[e].get(t).staged=!0;const r=[...s[e]];function a(t){const r=e?n.ee.get(e):n.ee,a=o.X.handlers;if(r.backlog&&a){var s=r.backlog[t],c=a[t];if(c){for(var u=0;s&&u {let[t,r]=e;return r.staged}))&&(r.sort(((e,t)=>e[1].priority-t[1].priority)),r.forEach((e=>{let[t]=e;a(t)})))}function f(e,t){var r=e[1];(0,i.D)(t[r],(function(t,r){var n=e[0];if(r[0]===n){var i=r[1],o=e[3],a=e[2];i.apply(o,a)}}))}},2177:(e,t,r)=>{r.d(t,{c:()=>f,ee:()=>u});var n=r(8632),i=r(2210),o=r(1284),a=r(5763),s="nr@context";let c=(0,n.fP)();var u;function d(){}function f(e){return(0,i.X)(e,s,l)}function l(){return new d}function h(){u.aborted=!0,u.backlog={}}c.ee?u=c.ee:(u=function e(t,r){var n={},c={},f={},g=!1;try{g=16===r.length&&(0,a.OP)(r).isolatedBacklog}catch(e){}var p={on:b,addEventListener:b,removeEventListener:y,emit:v,get:x,listeners:w,context:m,buffer:A,abort:h,aborted:!1,isBuffering:E,debugId:r,backlog:g?{}:t&&"object"==typeof t.backlog?t.backlog:{}};return p;function m(e){return e&&e instanceof d?e:e?(0,i.X)(e,s,l):l()}function v(e,r,n,i,o){if(!1!==o&&(o=!0),!u.aborted||i){t&&o&&t.emit(e,r,n);for(var a=m(n),s=w(e),d=s.length,f=0;fn,p:()=>i});var n=r(2177).ee.get("handle");function i(e,t,r,i,o){o?(o.buffer([e],i),o.emit(e,t,r)):(n.buffer([e],i),n.emit(e,t,r))}},4322:(e,t,r)=>{r.d(t,{X:()=>o});var n=r(5546);o.on=a;var i=o.handlers={};function o(e,t,r,o){a(o||n.E,i,e,t,r)}function a(e,t,r,i,o){o||(o="feature"),e||(e=n.E);var a=t[o]=t[o]||{};(a[r]=a[r]||[]).push([e,i])}},3239:(e,t,r)=>{r.d(t,{bP:()=>s,iz:()=>c,m$:()=>a});var n=r(385);let i=!1,o=!1;try{const e={get passive(){return i=!0,!1},get signal(){return o=!0,!1}};n._A.addEventListener("test",null,e),n._A.removeEventListener("test",null,e)}catch(e){}function a(e,t){return i||o?{capture:!!e,passive:i,signal:t}:!!e}function s(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;window.addEventListener(e,t,a(r,n))}function c(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2],n=arguments.length>3?arguments[3]:void 0;document.addEventListener(e,t,a(r,n))}},4402:(e,t,r)=>{r.d(t,{Ht:()=>u,M:()=>c,Rl:()=>a,ky:()=>s});var n=r(385);const i="xxxxxxxx-xxxx-4xxx-yxxx-xxxxxxxxxxxx";function o(e,t){return e?15&e[t]:16*Math.random()|0}function a(){const e=n._A?.crypto||n._A?.msCrypto;let t,r=0;return e&&e.getRandomValues&&(t=e.getRandomValues(new Uint8Array(31))),i.split("").map((e=>"x"===e?o(t,++r).toString(16):"y"===e?(3&o()|8).toString(16):e)).join("")}function s(e){const t=n._A?.crypto||n._A?.msCrypto;let r,i=0;t&&t.getRandomValues&&(r=t.getRandomValues(new Uint8Array(31)));const a=[];for(var s=0;s {r.d(t,{Bq:()=>n,Hb:()=>o,oD:()=>i});const n="NRBA",i=144e5,o=18e5},7894:(e,t,r)=>{function n(){return Math.round(performance.now())}r.d(t,{z:()=>n})},7243:(e,t,r)=>{r.d(t,{e:()=>o});var n=r(385),i={};function o(e){if(e in i)return i[e];if(0===(e||"").indexOf("data:"))return{protocol:"data"};let t;var r=n._A?.location,o={};if(n.il)t=document.createElement("a"),t.href=e;else try{t=new URL(e,r.href)}catch(e){return o}o.port=t.port;var a=t.href.split("://");!o.port&&a[1]&&(o.port=a[1].split("/")[0].split("@").pop().split(":")[1]),o.port&&"0"!==o.port||(o.port="https"===a[0]?"443":"80"),o.hostname=t.hostname||r.hostname,o.pathname=t.pathname,o.protocol=a[0],"/"!==o.pathname.charAt(0)&&(o.pathname="/"+o.pathname);var s=!t.protocol||":"===t.protocol||t.protocol===r.protocol,c=t.hostname===r.hostname&&t.port===r.port;return o.sameOrigin=s&&(!t.hostname||c),"/"===o.pathname&&(i[e]=o),o}},50:(e,t,r)=>{function n(e,t){"function"==typeof console.warn&&(console.warn("New Relic: ".concat(e)),t&&console.warn(t))}r.d(t,{Z:()=>n})},2587:(e,t,r)=>{r.d(t,{N:()=>c,T:()=>u});var n=r(2177),i=r(5546),o=r(8e3),a=r(3325);const s={stn:[a.D.sessionTrace],err:[a.D.jserrors,a.D.metrics],ins:[a.D.pageAction],spa:[a.D.spa],sr:[a.D.sessionReplay,a.D.sessionTrace]};function c(e,t){const r=n.ee.get(t);e&&"object"==typeof e&&(Object.entries(e).forEach((e=>{let[t,n]=e;void 0===u[t]&&(s[t]?s[t].forEach((e=>{n?(0,i.p)("feat-"+t,[],void 0,e,r):(0,i.p)("block-"+t,[],void 0,e,r),(0,i.p)("rumresp-"+t,[Boolean(n)],void 0,e,r)})):n&&(0,i.p)("feat-"+t,[],void 0,void 0,r),u[t]=Boolean(n))})),Object.keys(s).forEach((e=>{void 0===u[e]&&(s[e]?.forEach((t=>(0,i.p)("rumresp-"+e,[!1],void 0,t,r))),u[e]=!1)})),(0,o.L)(t,a.D.pageViewEvent))}const u={}},2210:(e,t,r)=>{r.d(t,{X:()=>i});var n=Object.prototype.hasOwnProperty;function i(e,t,r){if(n.call(e,t))return e[t];var i=r();if(Object.defineProperty&&Object.keys)try{return Object.defineProperty(e,t,{value:i,writable:!0,enumerable:!1}),i}catch(e){}return e[t]=i,i}},1284:(e,t,r)=>{r.d(t,{D:()=>n});const n=(e,t)=>Object.entries(e||{}).map((e=>{let[r,n]=e;return t(r,n)}))},4351:(e,t,r)=>{r.d(t,{P:()=>o});var n=r(2177);const i=()=>{const e=new WeakSet;return(t,r)=>{if("object"==typeof r&&null!==r){if(e.has(r))return;e.add(r)}return r}};function o(e){try{return JSON.stringify(e,i())}catch(e){try{n.ee.emit("internal-error",[e])}catch(e){}}}},3960:(e,t,r)=>{r.d(t,{K:()=>a,b:()=>o});var n=r(3239);function i(){return"undefined"==typeof document||"complete"===document.readyState}function o(e,t){if(i())return e();(0,n.bP)("load",e,t)}function a(e){if(i())return e();(0,n.iz)("DOMContentLoaded",e)}},8632:(e,t,r)=>{r.d(t,{EZ:()=>u,Qy:()=>c,ce:()=>o,fP:()=>a,gG:()=>d,mF:()=>s});var n=r(7894),i=r(385);const o={beacon:"bam.nr-data.net",errorBeacon:"bam.nr-data.net"};function a(){return i._A.NREUM||(i._A.NREUM={}),void 0===i._A.newrelic&&(i._A.newrelic=i._A.NREUM),i._A.NREUM}function s(){let e=a();return e.o||(e.o={ST:i._A.setTimeout,SI:i._A.setImmediate,CT:i._A.clearTimeout,XHR:i._A.XMLHttpRequest,REQ:i._A.Request,EV:i._A.Event,PR:i._A.Promise,MO:i._A.MutationObserver,FETCH:i._A.fetch}),e}function c(e,t,r){let i=a();const o=i.initializedAgents||{},s=o[e]||{};return Object.keys(s).length||(s.initializedAt={ms:(0,n.z)(),date:new Date}),i.initializedAgents={...o,[e]:{...s,[r]:t}},i}function u(e,t){a()[e]=t}function d(){return function(){let e=a();const t=e.info||{};e.info={beacon:o.beacon,errorBeacon:o.errorBeacon,...t}}(),function(){let e=a();const t=e.init||{};e.init={...t}}(),s(),function(){let e=a();const t=e.loader_config||{};e.loader_config={...t}}(),a()}},7956:(e,t,r)=>{r.d(t,{N:()=>i});var n=r(3239);function i(e){let t=arguments.length>1&&void 0!==arguments[1]&&arguments[1],r=arguments.length>2?arguments[2]:void 0,i=arguments.length>3?arguments[3]:void 0;return void(0,n.iz)("visibilitychange",(function(){if(t)return void("hidden"==document.visibilityState&&e());e(document.visibilityState)}),r,i)}},1214:(e,t,r)=>{r.d(t,{em:()=>v,u5:()=>N,QU:()=>S,_L:()=>I,Gm:()=>L,Lg:()=>M,gy:()=>U,BV:()=>Q,Kf:()=>ee});var n=r(2177);const i="nr@original";var o=Object.prototype.hasOwnProperty,a=!1;function s(e,t){return e||(e=n.ee),r.inPlace=function(e,t,n,i,o){n||(n="");var a,s,c,u="-"===n.charAt(0);for(c=0;c 2?n-2:0),o=2;o {r(A[T],e,w),r(E[T],e,w)})),r(l._A,"fetch",y),t.on(y+"end",(function(e,r){var n=this;if(r){var i=r.headers.get("content-length");null!==i&&(n.rxSize=i),t.emit(y+"done",[null,r],n)}else t.emit(y+"done",[e],n)})),t}const O={},j=["pushState","replaceState"];function S(e){const t=function(e){return(e||n.ee).get("history")}(e);return!l.il||O[t.debugId]++||(O[t.debugId]=1,s(t).inPlace(window.history,j,"-")),t}var P=r(3239);const C={},R=["appendChild","insertBefore","replaceChild"];function I(e){const t=function(e){return(e||n.ee).get("jsonp")}(e);if(!l.il||C[t.debugId])return t;C[t.debugId]=!0;var r=s(t),i=/[?&](?:callback|cb)=([^&#]+)/,o=/(.*)\.([^.]+)/,a=/^(\w+)(\.|$)(.*)$/;function c(e,t){var r=e.match(a),n=r[1],i=r[3];return i?c(i,t[n]):t[n]}return r.inPlace(Node.prototype,R,"dom-"),t.on("dom-start",(function(e){!function(e){if(!e||"string"!=typeof e.nodeName||"script"!==e.nodeName.toLowerCase())return;if("function"!=typeof e.addEventListener)return;var n=(a=e.src,s=a.match(i),s?s[1]:null);var a,s;if(!n)return;var u=function(e){var t=e.match(o);if(t&&t.length>=3)return{key:t[2],parent:c(t[1],window)};return{key:e,parent:window}}(n);if("function"!=typeof u.parent[u.key])return;var d={};function f(){t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}function l(){t.emit("jsonp-error",[],d),t.emit("jsonp-end",[],d),e.removeEventListener("load",f,(0,P.m$)(!1)),e.removeEventListener("error",l,(0,P.m$)(!1))}r.inPlace(u.parent,[u.key],"cb-",d),e.addEventListener("load",f,(0,P.m$)(!1)),e.addEventListener("error",l,(0,P.m$)(!1)),t.emit("new-jsonp",[e.src],d)}(e[0])})),t}var k=r(5763);const H={};function L(e){const t=function(e){return(e||n.ee).get("mutation")}(e);if(!l.il||H[t.debugId])return t;H[t.debugId]=!0;var r=s(t),i=k.Yu.MO;return i&&(window.MutationObserver=function(e){return this instanceof i?new i(r(e,"fn-")):i.apply(this,arguments)},MutationObserver.prototype=i.prototype),t}const z={};function M(e){const t=function(e){return(e||n.ee).get("promise")}(e);if(z[t.debugId])return t;z[t.debugId]=!0;var r=n.c,o=s(t),a=k.Yu.PR;return a&&function(){function e(r){var n=t.context(),i=o(r,"executor-",n,null,!1);const s=Reflect.construct(a,[i],e);return t.context(s).getCtx=function(){return n},s}l._A.Promise=e,Object.defineProperty(e,"name",{value:"Promise"}),e.toString=function(){return a.toString()},Object.setPrototypeOf(e,a),["all","race"].forEach((function(r){const n=a[r];e[r]=function(e){let i=!1;[...e||[]].forEach((e=>{this.resolve(e).then(a("all"===r),a(!1))}));const o=n.apply(this,arguments);return o;function a(e){return function(){t.emit("propagate",[null,!i],o,!1,!1),i=i||!e}}}})),["resolve","reject"].forEach((function(r){const n=a[r];e[r]=function(e){const r=n.apply(this,arguments);return e!==r&&t.emit("propagate",[e,!0],r,!1,!1),r}})),e.prototype=a.prototype;const n=a.prototype.then;a.prototype.then=function(){var e=this,i=r(e);i.promise=e;for(var a=arguments.length,s=new Array(a),c=0;c e())),t};function m(e,t){i.inPlace(t,["onreadystatechange"],"fn-",E)}function b(){var e=this,t=r.context(e);e.readyState>3&&!t.resolved&&(t.resolved=!0,r.emit("xhr-resolved",[],e)),i.inPlace(e,f,"fn-",E)}if(function(e,t){for(var r in e)t[r]=e[r]}(o,p),p.prototype=o.prototype,i.inPlace(p.prototype,J,"-xhr-",E),r.on("send-xhr-start",(function(e,t){m(e,t),function(e){h.push(e),a&&(y?y.then(A):u?u(A):(w=-w,x.data=w))}(t)})),r.on("open-xhr-start",m),a){var y=c&&c.resolve();if(!u&&!c){var w=1,x=document.createTextNode(w);new a(A).observe(x,{characterData:!0})}}else t.on("fn-end",(function(e){e[0]&&e[0].type===d||A()}));function A(){for(var e=0;e {r.d(t,{t:()=>n});const n=r(3325).D.ajax},6660:(e,t,r)=>{r.d(t,{A:()=>i,t:()=>n});const n=r(3325).D.jserrors,i="nr@seenError"},3081:(e,t,r)=>{r.d(t,{gF:()=>o,mY:()=>i,t9:()=>n,vz:()=>s,xS:()=>a});const n=r(3325).D.metrics,i="sm",o="cm",a="storeSupportabilityMetrics",s="storeEventMetrics"},4649:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageAction},7633:(e,t,r)=>{r.d(t,{Dz:()=>i,OJ:()=>a,qw:()=>o,t9:()=>n});const n=r(3325).D.pageViewEvent,i="firstbyte",o="domcontent",a="windowload"},9251:(e,t,r)=>{r.d(t,{t:()=>n});const n=r(3325).D.pageViewTiming},3614:(e,t,r)=>{r.d(t,{BST_RESOURCE:()=>i,END:()=>s,FEATURE_NAME:()=>n,FN_END:()=>u,FN_START:()=>c,PUSH_STATE:()=>d,RESOURCE:()=>o,START:()=>a});const n=r(3325).D.sessionTrace,i="bstResource",o="resource",a="-start",s="-end",c="fn"+a,u="fn"+s,d="pushState"},7836:(e,t,r)=>{r.d(t,{BODY:()=>A,CB_END:()=>E,CB_START:()=>u,END:()=>x,FEATURE_NAME:()=>i,FETCH:()=>_,FETCH_BODY:()=>v,FETCH_DONE:()=>m,FETCH_START:()=>p,FN_END:()=>c,FN_START:()=>s,INTERACTION:()=>l,INTERACTION_API:()=>d,INTERACTION_EVENTS:()=>o,JSONP_END:()=>b,JSONP_NODE:()=>g,JS_TIME:()=>T,MAX_TIMER_BUDGET:()=>a,REMAINING:()=>f,SPA_NODE:()=>h,START:()=>w,originalSetTimeout:()=>y});var n=r(5763);const i=r(3325).D.spa,o=["click","submit","keypress","keydown","keyup","change"],a=999,s="fn-start",c="fn-end",u="cb-start",d="api-ixn-",f="remaining",l="interaction",h="spaNode",g="jsonpNode",p="fetch-start",m="fetch-done",v="fetch-body-",b="jsonp-end",y=n.Yu.ST,w="-start",x="-end",A="-body",E="cb"+x,T="jsTime",_="fetch"},5938:(e,t,r)=>{r.d(t,{W:()=>o});var n=r(5763),i=r(2177);class o{constructor(e,t,r){this.agentIdentifier=e,this.aggregator=t,this.ee=i.ee.get(e,(0,n.OP)(this.agentIdentifier).isolatedBacklog),this.featureName=r,this.blocked=!1}}},9144:(e,t,r)=>{r.d(t,{j:()=>m});var n=r(3325),i=r(5763),o=r(5546),a=r(2177),s=r(7894),c=r(8e3),u=r(3960),d=r(385),f=r(50),l=r(3081),h=r(8632);function g(){const e=(0,h.gG)();["setErrorHandler","finished","addToTrace","inlineHit","addRelease","addPageAction","setCurrentRouteName","setPageViewName","setCustomAttribute","interaction","noticeError","setUserId"].forEach((t=>{e[t]=function(){for(var r=arguments.length,n=new Array(r),i=0;i 1?r-1:0),i=1;i {e.exposed&&e.api[t]&&o.push(e.api[t](...n))})),o.length>1?o:o[0]}(t,...n)}}))}var p=r(2587);function m(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:{},m=arguments.length>2?arguments[2]:void 0,v=arguments.length>3?arguments[3]:void 0,{init:b,info:y,loader_config:w,runtime:x={loaderType:m},exposed:A=!0}=t;const E=(0,h.gG)();y||(b=E.init,y=E.info,w=E.loader_config),(0,i.Dg)(e,b||{}),(0,i.GE)(e,w||{}),(0,i.sU)(e,x),y.jsAttributes??={},d.v6&&(y.jsAttributes.isWorker=!0),(0,i.CX)(e,y),g();const T=function(e,t){t||(0,c.R)(e,"api");const h={};var g=a.ee.get(e),p=g.get("tracer"),m="api-",v=m+"ixn-";function b(t,r,n,o){const a=(0,i.C5)(e);return null===r?delete a.jsAttributes[t]:(0,i.CX)(e,{...a,jsAttributes:{...a.jsAttributes,[t]:r}}),x(m,n,!0,o||null===r?"session":void 0)(t,r)}function y(){}["setErrorHandler","finished","addToTrace","inlineHit","addRelease"].forEach((e=>h[e]=x(m,e,!0,"api"))),h.addPageAction=x(m,"addPageAction",!0,n.D.pageAction),h.setCurrentRouteName=x(m,"routeName",!0,n.D.spa),h.setPageViewName=function(t,r){if("string"==typeof t)return"/"!==t.charAt(0)&&(t="/"+t),(0,i.OP)(e).customTransaction=(r||"http://custom.transaction")+t,x(m,"setPageViewName",!0)()},h.setCustomAttribute=function(e,t){let r=arguments.length>2&&void 0!==arguments[2]&&arguments[2];if("string"==typeof e){if(["string","number"].includes(typeof t)||null===t)return b(e,t,"setCustomAttribute",r);(0,f.Z)("Failed to execute setCustomAttribute.\nNon-null value must be a string or number type, but a type of was provided."))}else(0,f.Z)("Failed to execute setCustomAttribute.\nName must be a string type, but a type of was provided."))},h.setUserId=function(e){if("string"==typeof e||null===e)return b("enduser.id",e,"setUserId",!0);(0,f.Z)("Failed to execute setUserId.\nNon-null value must be a string type, but a type of was provided."))},h.interaction=function(){return(new y).get()};var w=y.prototype={createTracer:function(e,t){var r={},i=this,a="function"==typeof t;return(0,o.p)(v+"tracer",[(0,s.z)(),e,r],i,n.D.spa,g),function(){if(p.emit((a?"":"no-")+"fn-start",[(0,s.z)(),i,a],r),a)try{return t.apply(this,arguments)}catch(e){throw p.emit("fn-err",[arguments,this,"string"==typeof e?new Error(e):e],r),e}finally{p.emit("fn-end",[(0,s.z)()],r)}}}};function x(e,t,r,i){return function(){return(0,o.p)(l.xS,["API/"+t+"/called"],void 0,n.D.metrics,g),i&&(0,o.p)(e+t,[(0,s.z)(),...arguments],r?null:this,i,g),r?void 0:this}}function A(){r.e(439).then(r.bind(r,7438)).then((t=>{let{setAPI:r}=t;r(e),(0,c.L)(e,"api")})).catch((()=>(0,f.Z)("Downloading runtime APIs failed...")))}return["actionText","setName","setAttribute","save","ignore","onEnd","getContext","end","get"].forEach((e=>{w[e]=x(v,e,void 0,n.D.spa)})),h.noticeError=function(e,t){"string"==typeof e&&(e=new Error(e)),(0,o.p)(l.xS,["API/noticeError/called"],void 0,n.D.metrics,g),(0,o.p)("err",[e,(0,s.z)(),!1,t],void 0,n.D.jserrors,g)},d.il?(0,u.b)((()=>A()),!0):A(),h}(e,v);return(0,h.Qy)(e,T,"api"),(0,h.Qy)(e,A,"exposed"),(0,h.EZ)("activatedFeatures",p.T),T}},3325:(e,t,r)=>{r.d(t,{D:()=>n,p:()=>i});const n={ajax:"ajax",jserrors:"jserrors",metrics:"metrics",pageAction:"page_action",pageViewEvent:"page_view_event",pageViewTiming:"page_view_timing",sessionReplay:"session_replay",sessionTrace:"session_trace",spa:"spa"},i={[n.pageViewEvent]:1,[n.pageViewTiming]:2,[n.metrics]:3,[n.jserrors]:4,[n.ajax]:5,[n.sessionTrace]:6,[n.pageAction]:7,[n.spa]:8,[n.sessionReplay]:9}}},n={};function i(e){var t=n[e];if(void 0!==t)return t.exports;var o=n[e]={exports:{}};return r[e](o,o.exports,i),o.exports}i.m=r,i.d=(e,t)=>{for(var r in t)i.o(t,r)&&!i.o(e,r)&&Object.defineProperty(e,r,{enumerable:!0,get:t[r]})},i.f={},i.e=e=>Promise.all(Object.keys(i.f).reduce(((t,r)=>(i.f[r](e,t),t)),[])),i.u=e=>(({78:"page_action-aggregate",147:"metrics-aggregate",242:"session-manager",317:"jserrors-aggregate",348:"page_view_timing-aggregate",412:"lazy-feature-loader",439:"async-api",538:"recorder",590:"session_replay-aggregate",675:"compressor",733:"session_trace-aggregate",786:"page_view_event-aggregate",873:"spa-aggregate",898:"ajax-aggregate"}[e]||e)+"."+{78:"ac76d497",147:"3dc53903",148:"1a20d5fe",242:"2a64278a",317:"49e41428",348:"bd6de33a",412:"2f55ce66",439:"30bd804e",538:"1b18459f",590:"cf0efb30",675:"ae9f91a8",733:"83105561",786:"06482edd",860:"03a8b7a5",873:"e6b09d52",898:"998ef92b"}[e]+"-1.236.0.min.js"),i.o=(e,t)=>Object.prototype.hasOwnProperty.call(e,t),e={},t="NRBA:",i.l=(r,n,o,a)=>{if(e[r])e[r].push(n);else{var s,c;if(void 0!==o)for(var u=document.getElementsByTagName("script"),d=0;d {s.onerror=s.onload=null,clearTimeout(h);var i=e[r];if(delete e[r],s.parentNode&&s.parentNode.removeChild(s),i&&i.forEach((e=>e(n))),t)return t(n)},h=setTimeout(l.bind(null,void 0,{type:"timeout",target:s}),12e4);s.onerror=l.bind(null,s.onerror),s.onload=l.bind(null,s.onload),c&&document.head.appendChild(s)}},i.r=e=>{"undefined"!=typeof Symbol&&Symbol.toStringTag&&Object.defineProperty(e,Symbol.toStringTag,{value:"Module"}),Object.defineProperty(e,"__esModule",{value:!0})},i.j=364,i.p="https://js-agent.newrelic.com/",(()=>{var e={364:0,953:0};i.f.j=(t,r)=>{var n=i.o(e,t)?e[t]:void 0;if(0!==n)if(n)r.push(n[2]);else{var o=new Promise(((r,i)=>n=e[t]=[r,i]));r.push(n[2]=o);var a=i.p+i.u(t),s=new Error;i.l(a,(r=>{if(i.o(e,t)&&(0!==(n=e[t])&&(e[t]=void 0),n)){var o=r&&("load"===r.type?"missing":r.type),a=r&&r.target&&r.target.src;s.message="Loading chunk "+t+" failed.\n("+o+": "+a+")",s.name="ChunkLoadError",s.type=o,s.request=a,n[1](s)}}),"chunk-"+t,t)}};var t=(t,r)=>{var n,o,[a,s,c]=r,u=0;if(a.some((t=>0!==e[t]))){for(n in s)i.o(s,n)&&(i.m[n]=s[n]);if(c)c(i)}for(t&&t(r);u {i.r(o);var e=i(3325),t=i(5763);const r=Object.values(e.D);function n(e){const n={};return r.forEach((r=>{n[r]=function(e,r){return!1!==(0,t.Mt)(r,"".concat(e,".enabled"))}(r,e)})),n}var a=i(9144);var s=i(5546),c=i(385),u=i(8e3),d=i(5938),f=i(3960),l=i(50);class h extends d.W{constructor(e,t,r){let n=!(arguments.length>3&&void 0!==arguments[3])||arguments[3];super(e,t,r),this.auto=n,this.abortHandler,this.featAggregate,this.onAggregateImported,n&&(0,u.R)(e,r)}importAggregator(){let e=arguments.length>0&&void 0!==arguments[0]?arguments[0]:{};if(this.featAggregate||!this.auto)return;const r=c.il&&!0===(0,t.Mt)(this.agentIdentifier,"privacy.cookies_enabled");let n;this.onAggregateImported=new Promise((e=>{n=e}));const o=async()=>{let t;try{if(r){const{setupAgentSession:e}=await Promise.all([i.e(860),i.e(242)]).then(i.bind(i,3228));t=e(this.agentIdentifier)}}catch(e){(0,l.Z)("A problem occurred when starting up session manager. This page will not start or extend any session.",e)}try{if(!this.shouldImportAgg(this.featureName,t))return void(0,u.L)(this.agentIdentifier,this.featureName);const{lazyFeatureLoader:r}=await i.e(412).then(i.bind(i,8582)),{Aggregate:o}=await r(this.featureName,"aggregate");this.featAggregate=new o(this.agentIdentifier,this.aggregator,e),n(!0)}catch(e){(0,l.Z)("Downloading and initializing ".concat(this.featureName," failed..."),e),this.abortHandler?.(),n(!1)}};c.il?(0,f.b)((()=>o()),!0):o()}shouldImportAgg(r,n){return r!==e.D.sessionReplay||!1!==(0,t.Mt)(this.agentIdentifier,"session_trace.enabled")&&(!!n?.isNew||!!n?.state.sessionReplay)}}var g=i(7633),p=i(7894);class m extends h{static featureName=g.t9;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];if(super(r,n,g.t9,i),("undefined"==typeof PerformanceNavigationTiming||c.Tt)&&"undefined"!=typeof PerformanceTiming){const n=(0,t.OP)(r);n[g.Dz]=Math.max(Date.now()-n.offset,0),(0,f.K)((()=>n[g.qw]=Math.max((0,p.z)()-n[g.Dz],0))),(0,f.b)((()=>{const t=(0,p.z)();n[g.OJ]=Math.max(t-n[g.Dz],0),(0,s.p)("timing",["load",t],void 0,e.D.pageViewTiming,this.ee)}))}this.importAggregator()}}var v=i(1117),b=i(1284);class y extends v.w{constructor(e){super(e),this.aggregatedData={}}store(e,t,r,n,i){var o=this.getBucket(e,t,r,i);return o.metrics=function(e,t){t||(t={count:0});return t.count+=1,(0,b.D)(e,(function(e,r){t[e]=w(r,t[e])})),t}(n,o.metrics),o}merge(e,t,r,n,i){var o=this.getBucket(e,t,n,i);if(o.metrics){var a=o.metrics;a.count+=r.count,(0,b.D)(r,(function(e,t){if("count"!==e){var n=a[e],i=r[e];i&&!i.c?a[e]=w(i.t,n):a[e]=function(e,t){if(!t)return e;t.c||(t=x(t.t));return t.min=Math.min(e.min,t.min),t.max=Math.max(e.max,t.max),t.t+=e.t,t.sos+=e.sos,t.c+=e.c,t}(i,a[e])}}))}else o.metrics=r}storeMetric(e,t,r,n){var i=this.getBucket(e,t,r);return i.stats=w(n,i.stats),i}getBucket(e,t,r,n){this.aggregatedData[e]||(this.aggregatedData[e]={});var i=this.aggregatedData[e][t];return i||(i=this.aggregatedData[e][t]={params:r||{}},n&&(i.custom=n)),i}get(e,t){return t?this.aggregatedData[e]&&this.aggregatedData[e][t]:this.aggregatedData[e]}take(e){for(var t={},r="",n=!1,i=0;i t.max&&(t.max=e),e 2&&void 0!==arguments[2])||arguments[2];super(e,r,j.t,n),c.il&&((0,t.OP)(e).initHidden=Boolean("hidden"===document.visibilityState),(0,N.N)((()=>(0,s.p)("docHidden",[(0,p.z)()],void 0,j.t,this.ee)),!0),(0,O.bP)("pagehide",(()=>(0,s.p)("winPagehide",[(0,p.z)()],void 0,j.t,this.ee))),this.importAggregator())}}var P=i(3081);class C extends h{static featureName=P.t9;constructor(e,t){let r=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(e,t,P.t9,r),this.importAggregator()}}var R,I=i(2210),k=i(1214),H=i(2177),L={};try{R=localStorage.getItem("__nr_flags").split(","),console&&"function"==typeof console.log&&(L.console=!0,-1!==R.indexOf("dev")&&(L.dev=!0),-1!==R.indexOf("nr_dev")&&(L.nrDev=!0))}catch(e){}function z(e){try{L.console&&z(e)}catch(e){}}L.nrDev&&H.ee.on("internal-error",(function(e){z(e.stack)})),L.dev&&H.ee.on("fn-err",(function(e,t,r){z(r.stack)})),L.dev&&(z("NR AGENT IN DEVELOPMENT MODE"),z("flags: "+(0,b.D)(L,(function(e,t){return e})).join(", ")));var M=i(6660);class B extends h{static featureName=M.t;constructor(r,n){let i=!(arguments.length>2&&void 0!==arguments[2])||arguments[2];super(r,n,M.t,i),this.skipNext=0;try{this.removeOnAbort=new AbortController}catch(e){}const o=this;o.ee.on("fn-start",(function(e,t,r){o.abortHandler&&(o.skipNext+=1)})),o.ee.on("fn-err",(function(t,r,n){o.abortHandler&&!n[M.A]&&((0,I.X)(n,M.A,(function(){return!0})),this.thrown=!0,(0,s.p)("err",[n,(0,p.z)()],void 0,e.D.jserrors,o.ee))})),o.ee.on("fn-end",(function(){o.abortHandler&&!this.thrown&&o.skipNext>0&&(o.skipNext-=1)})),o.ee.on("internal-error",(function(t){(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,o.ee)})),this.origOnerror=c._A.onerror,c._A.onerror=this.onerrorHandler.bind(this),c._A.addEventListener("unhandledrejection",(t=>{const r=function(e){let t="Unhandled Promise Rejection: ";if(e instanceof Error)try{return e.message=t+e.message,e}catch(t){return e}if(void 0===e)return new Error(t);try{return new Error(t+(0,D.P)(e))}catch(e){return new Error(t)}}(t.reason);(0,s.p)("err",[r,(0,p.z)(),!1,{unhandledPromiseRejection:1}],void 0,e.D.jserrors,this.ee)}),(0,O.m$)(!1,this.removeOnAbort?.signal)),(0,k.gy)(this.ee),(0,k.BV)(this.ee),(0,k.em)(this.ee),(0,t.OP)(r).xhrWrappable&&(0,k.Kf)(this.ee),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}onerrorHandler(t,r,n,i,o){"function"==typeof this.origOnerror&&this.origOnerror(...arguments);try{this.skipNext?this.skipNext-=1:(0,s.p)("err",[o||new F(t,r,n),(0,p.z)()],void 0,e.D.jserrors,this.ee)}catch(t){try{(0,s.p)("ierr",[t,(0,p.z)(),!0],void 0,e.D.jserrors,this.ee)}catch(e){}}return!1}}function F(e,t,r){this.message=e||"Uncaught error with no additional information",this.sourceURL=t,this.line=r}let U=1;const q="nr@id";function G(e){const t=typeof e;return!e||"object"!==t&&"function"!==t?-1:e===c._A?0:(0,I.X)(e,q,(function(){return U++}))}function V(e){if("string"==typeof e&&e.length)return e.length;if("object"==typeof e){if("undefined"!=typeof ArrayBuffer&&e instanceof ArrayBuffer&&e.byteLength)return e.byteLength;if("undefined"!=typeof Blob&&e instanceof Blob&&e.size)return e.size;if(!("undefined"!=typeof FormData&&e instanceof FormData))try{return(0,D.P)(e).length}catch(e){return}}}var X=i(7243);class W{constructor(e){this.agentIdentifier=e,this.generateTracePayload=this.generateTracePayload.bind(this),this.shouldGenerateTrace=this.shouldGenerateTrace.bind(this)}generateTracePayload(e){if(!this.shouldGenerateTrace(e))return null;var r=(0,t.DL)(this.agentIdentifier);if(!r)return null;var n=(r.accountID||"").toString()||null,i=(r.agentID||"").toString()||null,o=(r.trustKey||"").toString()||null;if(!n||!i)return null;var a=(0,_.M)(),s=(0,_.Ht)(),c=Date.now(),u={spanId:a,traceId:s,timestamp:c};return(e.sameOrigin||this.isAllowedOrigin(e)&&this.useTraceContextHeadersForCors())&&(u.traceContextParentHeader=this.generateTraceContextParentHeader(a,s),u.traceContextStateHeader=this.generateTraceContextStateHeader(a,c,n,i,o)),(e.sameOrigin&&!this.excludeNewrelicHeader()||!e.sameOrigin&&this.isAllowedOrigin(e)&&this.useNewrelicHeaderForCors())&&(u.newrelicHeader=this.generateTraceHeader(a,s,c,n,i,o)),u}generateTraceContextParentHeader(e,t){return"00-"+t+"-"+e+"-01"}generateTraceContextStateHeader(e,t,r,n,i){return i+"@nr=0-1-"+r+"-"+n+"-"+e+"----"+t}generateTraceHeader(e,t,r,n,i,o){if(!("function"==typeof c._A?.btoa))return null;var a={v:[0,1],d:{ty:"Browser",ac:n,ap:i,id:e,tr:t,ti:r}};return o&&n!==o&&(a.d.tk=o),btoa((0,D.P)(a))}shouldGenerateTrace(e){return this.isDtEnabled()&&this.isAllowedOrigin(e)}isAllowedOrigin(e){var r=!1,n={};if((0,t.Mt)(this.agentIdentifier,"distributed_tracing")&&(n=(0,t.P_)(this.agentIdentifier).distributed_tracing),e.sameOrigin)r=!0;else if(n.allowed_origins instanceof Array)for(var i=0;i 2&&void 0!==arguments[2])||arguments[2];super(r,n,Z.t,i),(0,t.OP)(r).xhrWrappable&&(this.dt=new W(r),this.handler=(e,t,r,n)=>(0,s.p)(e,t,r,n,this.ee),(0,k.u5)(this.ee),(0,k.Kf)(this.ee),function(r,n,i,o){function a(e){var t=this;t.totalCbs=0,t.called=0,t.cbTime=0,t.end=E,t.ended=!1,t.xhrGuids={},t.lastSize=null,t.loadCaptureCalled=!1,t.params=this.params||{},t.metrics=this.metrics||{},e.addEventListener("load",(function(r){_(t,e)}),(0,O.m$)(!1)),c.IF||e.addEventListener("progress",(function(e){t.lastSize=e.loaded}),(0,O.m$)(!1))}function s(e){this.params={method:e[0]},T(this,e[1]),this.metrics={}}function u(e,n){var i=(0,t.DL)(r);i.xpid&&this.sameOrigin&&n.setRequestHeader("X-NewRelic-ID",i.xpid);var a=o.generateTracePayload(this.parsedOrigin);if(a){var s=!1;a.newrelicHeader&&(n.setRequestHeader("newrelic",a.newrelicHeader),s=!0),a.traceContextParentHeader&&(n.setRequestHeader("traceparent",a.traceContextParentHeader),a.traceContextStateHeader&&n.setRequestHeader("tracestate",a.traceContextStateHeader),s=!0),s&&(this.dt=a)}}function d(e,t){var r=this.metrics,i=e[0],o=this;if(r&&i){var a=V(i);a&&(r.txSize=a)}this.startTime=(0,p.z)(),this.listener=function(e){try{"abort"!==e.type||o.loadCaptureCalled||(o.params.aborted=!0),("load"!==e.type||o.called===o.totalCbs&&(o.onloadCalled||"function"!=typeof t.onload)&&"function"==typeof o.end)&&o.end(t)}catch(e){try{n.emit("internal-error",[e])}catch(e){}}};for(var s=0;s 1?e[1]=i:e.push(i)}else e[0]&&e[0].headers&&s(e[0].headers,n)&&(this.dt=n);function s(e,t){var r=!1;return t.newrelicHeader&&(e.set("newrelic",t.newrelicHeader),r=!0),t.traceContextParentHeader&&(e.set("traceparent",t.traceContextParentHeader),t.traceContextStateHeader&&e.set("tracestate",t.traceContextStateHeader),r=!0),r}}function x(e,t){this.params={},this.metrics={},this.startTime=(0,p.z)(),this.dt=t,e.length>=1&&(this.target=e[0]),e.length>=2&&(this.opts=e[1]);var r,n=this.opts||{},i=this.target;"string"==typeof i?r=i:"object"==typeof i&&i instanceof Y?r=i.url:c._A?.URL&&"object"==typeof i&&i instanceof URL&&(r=i.href),T(this,r);var o=(""+(i&&i instanceof Y&&i.method||n.method||"GET")).toUpperCase();this.params.method=o,this.txSize=V(n.body)||0}function A(t,r){var n;this.endTime=(0,p.z)(),this.params||(this.params={}),this.params.status=r?r.status:0,"string"==typeof this.rxSize&&this.rxSize.length>0&&(n=+this.rxSize);var o={txSize:this.txSize,rxSize:n,duration:(0,p.z)()-this.startTime};i("xhr",[this.params,o,this.startTime,this.endTime,"fetch"],this,e.D.ajax)}function E(t){var r=this.params,n=this.metrics;if(!this.ended){this.ended=!0;for(var o=0;o 2&&void 0!==arguments[2])||arguments[2];super(e,t,we.t,r),this.importAggregator()}}new class{constructor(e){let t=arguments.length>1&&void 0!==arguments[1]?arguments[1]:(0,_.ky)(16);c._A?(this.agentIdentifier=t,this.sharedAggregator=new y({agentIdentifier:this.agentIdentifier}),this.features={},this.desiredFeatures=new Set(e.features||[]),this.desiredFeatures.add(m),Object.assign(this,(0,a.j)(this.agentIdentifier,e,e.loaderType||"agent")),this.start()):(0,l.Z)("Failed to initial the agent. Could not determine the runtime environment.")}get config(){return{info:(0,t.C5)(this.agentIdentifier),init:(0,t.P_)(this.agentIdentifier),loader_config:(0,t.DL)(this.agentIdentifier),runtime:(0,t.OP)(this.agentIdentifier)}}start(){const t="features";try{const r=n(this.agentIdentifier),i=[...this.desiredFeatures];i.sort(((t,r)=>e.p[t.featureName]-e.p[r.featureName])),i.forEach((t=>{if(r[t.featureName]||t.featureName===e.D.pageViewEvent){const n=function(t){switch(t){case e.D.ajax:return[e.D.jserrors];case e.D.sessionTrace:return[e.D.ajax,e.D.pageViewEvent];case e.D.sessionReplay:return[e.D.sessionTrace];case e.D.pageViewTiming:return[e.D.pageViewEvent];default:return[]}}(t.featureName);n.every((e=>r[e]))||(0,l.Z)("".concat(t.featureName," is enabled but one or more dependent features has been disabled (").concat((0,D.P)(n),"). This may cause unintended consequences or missing data...")),this.features[t.featureName]=new t(this.agentIdentifier,this.sharedAggregator)}})),(0,T.Qy)(this.agentIdentifier,this.features,t)}catch(e){(0,l.Z)("Failed to initialize all enabled instrument classes (agent aborted) -",e);for(const e in this.features)this.features[e].abortHandler?.();const r=(0,T.fP)();return delete r.initializedAgents[this.agentIdentifier]?.api,delete r.initializedAgents[this.agentIdentifier]?.[t],delete this.sharedAggregator,r.ee?.abort(),delete r.ee?.get(this.agentIdentifier),!1}}}({features:[J,m,S,class extends h{static featureName=oe;constructor(t,r){if(super(t,r,oe,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;const n=this.ee;let i;(0,k.QU)(n),this.eventsEE=(0,k.em)(n),this.eventsEE.on(se,(function(e,t){this.bstStart=(0,p.z)()})),this.eventsEE.on(ae,(function(t,r){(0,s.p)("bst",[t[0],r,this.bstStart,(0,p.z)()],void 0,e.D.sessionTrace,n)})),n.on(ce+ne,(function(e){this.time=(0,p.z)(),this.startPath=location.pathname+location.hash})),n.on(ce+ie,(function(t){(0,s.p)("bstHist",[location.pathname+location.hash,this.startPath,this.time],void 0,e.D.sessionTrace,n)}));try{i=new PerformanceObserver((t=>{const r=t.getEntries();(0,s.p)(te,[r],void 0,e.D.sessionTrace,n)})),i.observe({type:re,buffered:!0})}catch(e){}this.importAggregator({resourceObserver:i})}},C,xe,B,class extends h{static featureName=de;constructor(e,r){if(super(e,r,de,!(arguments.length>2&&void 0!==arguments[2])||arguments[2]),!c.il)return;if(!(0,t.OP)(e).xhrWrappable)return;try{this.removeOnAbort=new AbortController}catch(e){}let n,i=0;const o=this.ee.get("tracer"),a=(0,k._L)(this.ee),s=(0,k.Lg)(this.ee),u=(0,k.BV)(this.ee),d=(0,k.Kf)(this.ee),f=this.ee.get("events"),l=(0,k.u5)(this.ee),h=(0,k.QU)(this.ee),g=(0,k.Gm)(this.ee);function m(e,t){h.emit("newURL",[""+window.location,t])}function v(){i++,n=window.location.hash,this[ve]=(0,p.z)()}function b(){i--,window.location.hash!==n&&m(0,!0);var e=(0,p.z)();this[pe]=~~this[pe]+e-this[ve],this[ye]=e}function y(e,t){e.on(t,(function(){this[t]=(0,p.z)()}))}this.ee.on(ve,v),s.on(be,v),a.on(be,v),this.ee.on(ye,b),s.on(ge,b),a.on(ge,b),this.ee.buffer([ve,ye,"xhr-resolved"],this.featureName),f.buffer([ve],this.featureName),u.buffer(["setTimeout"+le,"clearTimeout"+fe,ve],this.featureName),d.buffer([ve,"new-xhr","send-xhr"+fe],this.featureName),l.buffer([me+fe,me+"-done",me+he+fe,me+he+le],this.featureName),h.buffer(["newURL"],this.featureName),g.buffer([ve],this.featureName),s.buffer(["propagate",be,ge,"executor-err","resolve"+fe],this.featureName),o.buffer([ve,"no-"+ve],this.featureName),a.buffer(["new-jsonp","cb-start","jsonp-error","jsonp-end"],this.featureName),y(l,me+fe),y(l,me+"-done"),y(a,"new-jsonp"),y(a,"jsonp-end"),y(a,"cb-start"),h.on("pushState-end",m),h.on("replaceState-end",m),window.addEventListener("hashchange",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("load",m,(0,O.m$)(!0,this.removeOnAbort?.signal)),window.addEventListener("popstate",(function(){m(0,i>1)}),(0,O.m$)(!0,this.removeOnAbort?.signal)),this.abortHandler=this.#e,this.importAggregator()}#e(){this.removeOnAbort?.abort(),this.abortHandler=void 0}}],loaderType:"spa"})})(),window.NRBA=o})(); window.jQuery || document.write(' ') CKEDITOR_BASEPATH='https://gatesopenresearch.org/js/vendor/ckeditor/' window.reactTheme = 'gates'; window.MathJax = { CommonHTML: { linebreaks: { automatic: true } }, 'HTML-CSS': { linebreaks: { automatic: true } }, SVG: { linebreaks: { automatic: true } }, AuthorInit: function() { MathJax.Hub.Register.MessageHook('End Process', function () { let timeout = false; // holder for timeout id const delay = 250; // delay after event is "complete" to run callback const reflowMath = function() { const dispFormulas = document.querySelectorAll('.disp-formula.panel'); if (!dispFormulas) { return; } for (const dispFormula of dispFormulas) { const child = dispFormula.querySelector('.MathJax_Preview').nextSibling.firstChild; const isMultiline = MathJax.Hub.getAllJax(dispFormula)[0].root.isMultiline; if (dispFormula.offsetWidth < child.offsetWidth || isMultiline) { MathJax.Hub.Queue(['Rerender', MathJax.Hub, dispFormula]); } } }; window.addEventListener('resize', function() { clearTimeout(timeout); // clear the timeout timeout = setTimeout(reflowMath, delay); // start timing for event "completion" }); }); }, }; if (window.location.hash == '#_=_'){ window.location = window.location.href.split('#')[0] } !function(f,b,e,v,n,t,s){if(f.fbq)return;n=f.fbq=function() {n.callMethod? n.callMethod.apply(n,arguments):n.queue.push(arguments)} ;if(!f._fbq)f._fbq=n; n.push=n;n.loaded=!0;n.version='2.0';n.queue=[];t=b.createElement(e);t.async=!0; t.src=v;s=b.getElementsByTagName(e)[0];s.parentNode.insertBefore(t,s)}(window, document,'script','https://connect.facebook.net/en_US/fbevents.js'); fbq('init', '1641728616063202'); fbq('track', "PixelInitialized", {}); Skip to content Gates Open Research file_upload Submit via VeriXiv search clear search menu close clear Search Browse Gateways & Collections How to Publish Submit via VeriXiv My Submissions Article Guidelines Article Guidelines (New Versions) Open Data, Software and Code Guidelines Open Data and Accessible Source Materials Guidelines (HSS) Prepublication Checks Production Process Posters and Slides Guidelines Document Guidelines Publication Charges Finding Article Reviewers About How it Works For Reviewers Our Advisors Policies Glossary FAQs For Developers Contact Blog My Account Submissions Content and Tracking Alerts My Details Sign In Submit via VeriXiv { "@context": "https://schema.org", "@type": "ScholarlyArticle", "mainEntityOfPage": { "@type": "WebPage", "@id": "https://gatesopenresearch.org/articles/8-95" }, "headline": "Single-blinded, stratified, dose ranging trial to assess pharmacokinetics and identify optimal dose of vitamin...", "datePublished": "2024-09-04T10:45:38", "dateModified": "2025-09-17T15:10:53", "author": [ { "@type": "Person", "name": "Omar Lweno" }, { "@type": "Person", "name": "Victoria S. Reynolds" }, { "@type": "Person", "name": "Matthew D. Barberio" }, { "@type": "Person", "name": "Kevin C. Klatt" }, { "@type": "Person", "name": "Sabina Mugusi" }, { "@type": "Person", "name": "Mathangi Gopalakrishnan" }, { "@type": "Person", "name": "Zohra Lukmanji" }, { "@type": "Person", "name": "Fadhlun M. Alwy Al-beity" }, { "@type": "Person", "name": "Homa K. Ahmadzia" }, { "@type": "Person", "name": "Amrita Arcot" }, { "@type": "Person", "name": "Kelly Gallagher" }, { "@type": "Person", "name": "Leigh A. Martin" }, { "@type": "Person", "name": "Ali Rahnavard" }, { "@type": "Person", "name": "Alison D. Gernand" }, { "@type": "Person", "name": "Brooke Langevin" }, { "@type": "Person", "name": "Honorati Masanja" }, { "@type": "Person", "name": "Emily R. Smith" } ], "publisher": { "@type": "Organization", "name": "Gates Open Research", "logo": { "@type": "ImageObject", "url": "https://gatesopenresearch.org/img/AMP/Gates_image.png", "height": 600, "width": 47 } }, "image": { "@type": "ImageObject", "url": "https://gatesopenresearch.org/img/AMP/Gates_image.png", "height": 1200, "width": 94 }, "description": " Background Vitamin B12 is an essential cofactor for two enzymes that have critical functions in pregnancy, both for maternal health and fetal development. However, the optimal supplemental dosage and its correlation with vitamin B12 status during pregnancy remain inadequately understood due to limited data. Methods This is a single-blinded, stratified, dose-ranging trial of vitamin B12 supplementation that will be conducted at the Ifakara Health Institute Bagamoyo Clinical Trial Unit in Bagamoyo, Tanzania. We will enroll 40 pregnant participants (gestational age 25–28 weeks) and 10 non-pregnant participants, stratified based on baseline vitamin B12 status (sufficient and insufficient). Pregnant participants are sequentially assigned to one of three doses: 2.6, 10, and 50 µg for four weeks. At the highest dose, pregnant participants are randomized to receive 50 µg once a day (Q24H) or 25 µg twice a day (Q12H). The two lower doses (2.6 and 10 µg) are given Q24H. Non-pregnant participants will receive 2.6 µg Q24H. The trial includes a four week in-patient phase for daily assessment and controlled feeding, with pregnant participants assessed once postpartum. Primary endpoints include serum B12 concentrations, holotranscobalamin concentrations, and their ratio after four weeks of daily supplementation. Discussion This study aims to deepen our understanding of nutrient requirements in pregnancy by generating high-quality, high-dimensional data. We will answer questions about how pre-supplementation vitamin B12 status and dosage impact vitamin B12 saturable absorption and steady-state over the course of four weeks. Limitations include our inability to assess pharmacokinetic changes across gestation, the impact of vitamin B12 status or supplementation on pregnancy and fetal/newborn health, comparing vitamin B12 effects between pregnant and non-pregnant individuals above the recommended dietary allowance (2.6 µg), and comparing Q12H and Q24H dosing at 50 µg. This is the first controlled feeding study to be conducted in sub-Saharan Africa. Registration ClinicalTrials.gov (NCT05426395, 16/06/2022). " } { "@context": "http://schema.org", "@type": "BreadcrumbList", "itemListElement": [ { "@type": "ListItem", "position": "1", "item": { "@id": "https://gatesopenresearch.org/", "name": "Home" } }, { "@type": "ListItem", "position": "2", "item": { "@id": "https://gatesopenresearch.org/browse/articles", "name": "Browse" } }, { "@type": "ListItem", "position": "3", "item": { "@id": "https://gatesopenresearch.org/articles/8-95/v1", "name": "Single-blinded, stratified, dose ranging trial to assess pharmacokinetics..." } } ] } Home Browse Single-blinded, stratified, dose ranging trial to assess pharmacokinetics... ALL Metrics - Views Downloads Get PDF Get XML Cite How to cite this article Lweno O, Reynolds VS, Barberio MD et al. Single-blinded, stratified, dose ranging trial to assess pharmacokinetics and identify optimal dose of vitamin B12 in pregnancy in Tanzania [version 1; peer review: 2 approved with reservations] . Gates Open Res 2024, 8 :95 ( https://doi.org/10.12688/gatesopenres.15991.1 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. Close Copy Citation Details Export Export Citation Sciwheel EndNote Ref. Manager Bibtex ProCite Sente EXPORT Select a format first Track Share ▬ ✚ Study Protocol Single-blinded, stratified, dose ranging trial to assess pharmacokinetics and identify optimal dose of vitamin B12 in pregnancy in Tanzania [version 1; peer review: 2 approved with reservations] Omar Lweno 1 , Victoria S. Reynolds https://orcid.org/0009-0002-8231-8137 2 , Matthew D. Barberio https://orcid.org/0000-0003-0468-7842 3 , [...] Kevin C. Klatt https://orcid.org/0000-0003-0223-8250 4 , Sabina Mugusi 5 , Mathangi Gopalakrishnan 6 , Zohra Lukmanji 1 , Fadhlun M. Alwy Al-beity https://orcid.org/0000-0003-2416-6876 7 , Homa K. Ahmadzia 8,9 , Amrita Arcot 10 , Kelly Gallagher 11 , Leigh A. Martin https://orcid.org/0000-0003-4812-7396 10 , Ali Rahnavard https://orcid.org/0000-0002-9710-0248 12 , Alison D. Gernand 10 , Brooke Langevin 6 , Honorati Masanja https://orcid.org/0000-0002-3860-7348 1 , Emily R. Smith https://orcid.org/0000-0001-5715-9459 2,3 Omar Lweno 1 , Victoria S. Reynolds https://orcid.org/0009-0002-8231-8137 2 , [...] Matthew D. Barberio https://orcid.org/0000-0003-0468-7842 3 , Kevin C. Klatt https://orcid.org/0000-0003-0223-8250 4 , Sabina Mugusi 5 , Mathangi Gopalakrishnan 6 , Zohra Lukmanji 1 , Fadhlun M. Alwy Al-beity https://orcid.org/0000-0003-2416-6876 7 , Homa K. Ahmadzia 8,9 , Amrita Arcot 10 , Kelly Gallagher 11 , Leigh A. Martin https://orcid.org/0000-0003-4812-7396 10 , Ali Rahnavard https://orcid.org/0000-0002-9710-0248 12 , Alison D. Gernand 10 , Brooke Langevin 6 , Honorati Masanja https://orcid.org/0000-0002-3860-7348 1 , Emily R. Smith https://orcid.org/0000-0001-5715-9459 2,3 PUBLISHED 04 Sep 2024 Author details Author details 1 Ifakara Health Institute, Dar es Salaam, Tanzania 2 Department of Global Health, The Milken Institute School of Public Health, The George Washington University, Washington, District of Columbia, 20052, USA 3 Department of Exercise and Nutrition Science, The Milken Institute School of Public Health, The George Washington University, Washington, District of Columbia, 20052, USA 4 Department of Nutritional Sciences and Toxicology, University of California Berkeley, Berkeley, California, 94720, USA 5 Department of Clinical Pharmacology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania 6 Center for Translational Medicine, School of Pharmacy, University of Maryland Baltimore, Baltimore, Maryland, 21201, USA 7 Department of Obstetrics and Gynecology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania 8 Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, The George Washington University, Washington, District of Columbia, 20052, USA 9 Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Inova Health System, Falls Church, VA, 22042, USA 10 Department of Nutritional Sciences, The Pennsylvania State University, University Park, Pennsylvania, 16802, USA 11 Ross and Carol Nese College of Nursing, The Pennsylvania State University - University Park Campus, University Park, Pennsylvania, 16802, USA 12 Computational Biology Institute, Departments of Biostatistics and Bioinformatics, The Milken Institute School of Public Health, The George Washington University, Washington, District of Columbia, 20052, USA Omar Lweno Roles: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Resources, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing Victoria S. Reynolds Roles: Project Administration, Resources, Writing – Original Draft Preparation, Writing – Review & Editing Matthew D. Barberio Roles: Conceptualization, Investigation, Methodology, Project Administration, Resources, Supervision, Validation, Visualization, Writing – Review & Editing Kevin C. Klatt Roles: Conceptualization, Investigation, Methodology, Project Administration, Resources, Supervision, Validation, Visualization, Writing – Review & Editing Sabina Mugusi Roles: Investigation, Project Administration, Resources, Supervision, Writing – Review & Editing Mathangi Gopalakrishnan Roles: Conceptualization, Formal Analysis, Methodology, Project Administration, Resources, Visualization, Writing – Review & Editing Zohra Lukmanji Roles: Project Administration, Resources, Supervision, Writing – Review & Editing Fadhlun M. Alwy Al-beity Roles: Project Administration, Supervision, Writing – Review & Editing Homa K. Ahmadzia Roles: Investigation, Project Administration, Resources, Supervision, Writing – Review & Editing Amrita Arcot Roles: Project Administration, Writing – Review & Editing Kelly Gallagher Roles: Project Administration, Writing – Review & Editing Leigh A. Martin Roles: Methodology, Project Administration, Writing – Review & Editing Ali Rahnavard Roles: Conceptualization, Methodology, Project Administration, Writing – Review & Editing Alison D. Gernand Roles: Conceptualization, Methodology, Project Administration, Resources, Supervision, Writing – Review & Editing Brooke Langevin Roles: Formal Analysis, Validation, Visualization, Writing – Review & Editing Honorati Masanja Roles: Conceptualization, Funding Acquisition, Investigation, Methodology, Project Administration, Software, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing Emily R. Smith Roles: Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Software, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing OPEN PEER REVIEW DETAILS REVIEWER STATUS Abstract Background Vitamin B12 is an essential cofactor for two enzymes that have critical functions in pregnancy, both for maternal health and fetal development. However, the optimal supplemental dosage and its correlation with vitamin B12 status during pregnancy remain inadequately understood due to limited data. Methods This is a single-blinded, stratified, dose-ranging trial of vitamin B12 supplementation that will be conducted at the Ifakara Health Institute Bagamoyo Clinical Trial Unit in Bagamoyo, Tanzania. We will enroll 40 pregnant participants (gestational age 25–28 weeks) and 10 non-pregnant participants, stratified based on baseline vitamin B12 status (sufficient and insufficient). Pregnant participants are sequentially assigned to one of three doses: 2.6, 10, and 50 µg for four weeks. At the highest dose, pregnant participants are randomized to receive 50 µg once a day (Q24H) or 25 µg twice a day (Q12H). The two lower doses (2.6 and 10 µg) are given Q24H. Non-pregnant participants will receive 2.6 µg Q24H. The trial includes a four week in-patient phase for daily assessment and controlled feeding, with pregnant participants assessed once postpartum. Primary endpoints include serum B12 concentrations, holotranscobalamin concentrations, and their ratio after four weeks of daily supplementation. Discussion This study aims to deepen our understanding of nutrient requirements in pregnancy by generating high-quality, high-dimensional data. We will answer questions about how pre-supplementation vitamin B12 status and dosage impact vitamin B12 saturable absorption and steady-state over the course of four weeks. Limitations include our inability to assess pharmacokinetic changes across gestation, the impact of vitamin B12 status or supplementation on pregnancy and fetal/newborn health, comparing vitamin B12 effects between pregnant and non-pregnant individuals above the recommended dietary allowance (2.6 µg), and comparing Q12H and Q24H dosing at 50 µg. This is the first controlled feeding study to be conducted in sub-Saharan Africa. Registration ClinicalTrials.gov (NCT05426395, 16/06/2022). READ ALL READ LESS Keywords Vitamin B12 Deficiency, Pregnancy, Controlled Feeding, Randomized Trial, Tanzania Corresponding Author(s) Emily R. Smith ( [email protected] ) Close Corresponding author: Emily R. Smith Competing interests: No competing interests were disclosed. Grant information: This work was supported by the Gates Foundation [INV-016930].The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the protocol manuscript. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Copyright: © 2024 Lweno O et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. How to cite: Lweno O, Reynolds VS, Barberio MD et al. Single-blinded, stratified, dose ranging trial to assess pharmacokinetics and identify optimal dose of vitamin B12 in pregnancy in Tanzania [version 1; peer review: 2 approved with reservations] . Gates Open Res 2024, 8 :95 ( https://doi.org/10.12688/gatesopenres.15991.1 ) First published: 04 Sep 2024, 8 :95 ( https://doi.org/10.12688/gatesopenres.15991.1 ) Latest published: 17 Sep 2025, 8 :95 ( https://doi.org/10.12688/gatesopenres.15991.2 )  There is a newer version of this article available. Suppress this message for one day. Introduction Background and rationale There is currently limited data regarding the pharmacokinetics of vitamin B12 and health outcomes related to maternal vitamin B12 status in pregnancy. It is important to understand the dose-response effects of vitamin B12 during pregnancy on nutrient and functional status markers and how maternal stores (baseline status) and gestational age modify this response. Although there are important knowledge gaps for many micronutrients in pregnancy, we have prioritized vitamin B12 for three reasons: (i) insufficient B12 intake is common in many lower middle-income countries (LMIC) 1 ; (ii) observational human data show that maternal vitamin B12 status is linked to adverse pregnancy outcomes 2 ; and (iii) emerging evidence suggests unique, pregnancy-related metabolic changes in functional vitamin B12 biomarkers (e.g. holotranscobalamin, homocysteine, methylmalonic acid 3 ), thus calling into question whether these biomarkers and their traditional cutoffs are appropriate for B12 deficiency screening during pregnancy. B12 is well established as a cofactor for two enzymes including methionine synthase and L-methylmalonyl-CoA mutase. Functionally, B12 is crucial for red blood cell formation, neurological functioning, and DNA synthesis. Adequate maternal B12 status is critical in ensuring placental or mammary transfer of cobalamin to the developing fetus or infant 1 , 4 . B12 plays an important role during the perinatal period; it facilitates neural myelination, brain development, and growth of the offspring, alongside maintaining normal maternal functions 2 . B12 deficiency causes megaloblastic anemia and related fatigue, weakness, and weight loss. It is often identified clinically by neurological problems including tingling or numbness in extremities, motor or visual disturbances, and cognitive problems (e.g., memory loss, disorientation, frank dementia) 2 . Subclinical B12 deficiency has recently been linked to several adverse maternal and neonatal health outcomes 2 . Observational data show links between maternal B12 deficiency and adverse pregnancy and birth outcomes, including spontaneous abortion, pre-eclampsia, intrauterine growth restriction (IUGR), and low birthweight 5 For example, one study of 478 women in India showed an association between maternal B12 deficiency during pregnancy and increased risk for IUGR 6 . Other studies have reported that elevated total homocysteine – typically observed when vitamin B12 status is compromised – is associated with low birth weight, independent of folate status 7 . Low maternal B12 status has also been associated with adverse neonatal development including disruption of myelination and altered behavioral development, as well as disturbed inflammatory processes 8 . There is evidence that infants born to mothers who maintain a vegan diet (and thus are likely B12 insufficient) are at increased risk of having low B12 stores at birth, and may develop overt signs of B12 deficiency within the first year of life 9 – 11 . However the existing body of evidence is based on low quality, observational data; evidence from high quality, prospective, and experimental studies are lacking 2 . While several studies in the 1960s-1980s suggest there are sex differences in average vitamin B12 serum levels 12 – 14 , there has been limited work to understand metabolism and special nutrient requirements for women in general, as well as pregnant and lactating women 15 . Based on limited evidence, it is generally thought that: (i) dietary B12 absorption increases during pregnancy, though the degree to which it does is not known 16 ; (ii) recent maternal intakes, not maternal stores, are the primary source of vitamin B12 transferred across the placenta to the fetal compartment in a well-nourished context 17 ; (iii) serum total vitamin B12 concentrations decline throughout pregnancy, possibly due to plasma volume expansion, whereas the bioactive form of vitamin B12, holotranscobalamin (holoTC), remains unchanged in observational cohorts of uncomplicated pregnancy 18 , 19 . Little is known about changes in the efficiency of enterohepatic recycling and renal handling of vitamin B12 during pregnancy. No experimental evidence of varying vitamin B12 intake in pregnancy was available for inclusion in the dietary reference intake (DRI) decision making process 15 . The estimated average requirement and/or recommended dietary allowance (EAR/RDA) for vitamin B12 during pregnancy were established by increasing the DRIs for non-pregnant women by 0.2 µg/day to account for the estimated average rates of fetal deposition. There is currently no evidence regarding adverse events or serious adverse events related to high B12 intake. Current nutrient reference values for B12 in pregnancy may be too low, even for women with otherwise adequate diets. One post hoc analysis of a controlled feeding study compared vitamin B12 metabolism in third-trimester pregnancy and lactation relative to non-pregnant women 3 . Despite dietary (food and supplemental) vitamin B12 intakes in this study that were three times the RDA for pregnancy, pregnant women exhibited serum vitamin B12 levels in the low- to mid-range of the ‘normal’ reference range. Findings suggest that normal values may be different in pregnancy or that consumption of RDA levels remain insufficient even for this well-nourished population consuming diets meeting the DRIs. Higher B12 intakes in the study increased holotranscobalamin levels from baseline. The functional consequence of this remains unknown, though this observation conflicts with observational reports suggesting stable holoTC levels across pregnancy 20 , suggesting this bioactive form of vitamin B12 is sensitive to higher intakes. Given that increased holoTC receptor availability has been observed in late pregnancy, it is critical to understand the relationship between vitamin B12 intake and holoTC, as this likely influences fetal stores 20 . Objectives We aim to: (i) enhance our understanding of vitamin B12 utilization and metabolic fate during pregnancy in people with sufficient and insufficient baseline B12 status; (ii) identify priority dose regimens of vitamin B12 that improve established vitamin B12 status indicators for investigation in later phase clinical trials to be conducted in populations where vitamin B12 insufficiency or deficiency is common; and (iii) identify novel biomarkers of vitamin B12 status appropriate for pregnancy. Reporting The study protocol was developed and reported according to the SPIRIT (Standard Protocol Items: Recommendations for Interventional Trials) 2013 Guidelines 21 , 22 and is available as extended data 23 . The schedule of enrollment, interventions, and assessments is shown under Table 1 . Table 1. Schedule of enrollment, interventions, and assessments (SPIRIT Figure). STUDY PERIOD Screening Baseline Post-allocation Close-out Timepoint Day -8 Day 0 Day 1–28 Day 29 6-weeks postpartum ENROLLMENT Eligibility screen X Informed consent X Randomization / Allocation X INTERVENTIONS 2.6 ug B12 10 ug B12 50 ug B12 ASSESSMENTS- MATERNAL Hemoglobin X Ultrasound X Demographics X Depression (PHQ-9) X X Food frequency questionnaire X Dietary recall X Height X Weight X X X X X Vital signs X X X X MUAC X X X X Blood sample X X X X Urine sample X X X X Breastmilk sample X ASSESSMENTS- INFANTS Stool sample X Weight X Trial design This is a single-blinded, stratified, multiple ascending dose trial. Pregnant participants will be stratified based on their baseline serum B12 status. Women with a baseline serum B12 concentration >220 pmol/L will proceed into the “Sufficient B12 Status” strata and women with ≤220 pmol/L will proceed in the “Insufficient or Deficient B12 Status” strata 10 . There are three ascending doses (2.6 µg, 10 µg, to 50 µg) that will be assessed in this trial. Each dose will have five participants assigned to it. Allocation to each dose group will be based on three factors: baseline B12 status, pregnancy status, and the timing of dosing (either every 12 hours or every 24 hours). Table 2 illustrates the dosing levels, timings, and stratification. We will begin with the lowest dose (2.6 µg) and complete the trial for participants in each group at this dose level before progressing to the next higher dose groups (10 µg to 50 µg). Additionally, non-pregnant females will be enrolled and will be stratified based on their baseline serum B12 status. There will be no dose escalation or Q12 regimen arm in the non-pregnant group. Non-pregnant participants will only be assessed at the Dose I (2.6 µg), once per day (Q24H) level. Table 2. Trial Design. N=5 participants will be enrolled in each group. Dose 1 (2.6 µg) Dose 2 (10 µg) Dose 3 (50 µg) Sufficient B12 Status serum B12 >220 pmol/L Pregnant Q12H - - Group 3a Q24H Group 1a Group 2a Group 3b Non-Pregnant Group 1b - - Insufficient B12 Status serum B12 ≤220 pmol/L Pregnant Q12H - - Group 3c Q24H Group 1c Group 2b Group 3d Non-Pregnant Group 1d - - Methods Tanzania Medicines & Medical Device Authority: TRC-WEB0023/CTR/-REG/0008, approved on May 3, 2023. Participants, interventions and outcomes Study setting In a previous study, the prevalence of vitamin B12 insufficiency among Tanzanian mothers in Dar es Salaam and Morogoro Regions was 25.6% three-months postpartum; insufficiency was found to be a key predictor of infant vitamin B12 deficiency 24 . Bagamoyo is a district located on the coast of Tanzania, approximately 60 km north of Dar es Salaam. The study will be conducted at the Ifakara Health Institute (IHI) Bagamoyo Clinical Trial Unit in Bagamoyo (BCTU) located on the Kingani Estate. The center has a track record of conducting good clinical practice (GCP) compliant phase 1, 2, and 3 studies including malaria sporozoite challenge studies, drug trials, and bioequivalence studies 25 – 27 . We modified the facility kitchen to serve as a metabolic kitchen that will be used for food preparation, refrigerated food storage, obtaining weighed food records, and dishwashing. The trial, comprising both supplementation and follow up, will last for four weeks in total, with one additional follow-up visit for pregnant participants on or after 6 weeks postpartum. Participants will remain inpatient for the four weeks of the study to facilitate the controlled feeding study component and ensure direct observation of the intervention vitamin B12 supplement. Eligibility criteria Research staff will assess eligibility criteria for pregnant and non-pregnant participants. The trial inclusion criteria for the pregnancy strata require that the participant is: (i) pregnant and female, (ii) has an estimated gestational age of 25 to 28 weeks at study initiation, (iii) is between the ages of 18 and 45 years of age, (iv) lives in the study area and does not plan to travel outside of the study area for the duration of the trial, and (v) consents to participate in the trial. The same eligibility criteria apply for those in the non-pregnant strata, less the pregnancy and gestational age requirements. The trial exclusion criteria for pregnant participants include: (i) known multiple pregnancy (e.g. twins, triplets), (ii) severe anemia (hemoglobin <7 g/dL), (iii) pre-pregnancy or early pregnancy body mass index (BMI) ≥ 35 kg/m 2 , (iv) self-reported pre-pregnancy history of type II diabetes mellitus, hypertension, or hypercholesterolemia, (v) currently diagnosed preeclampsia or eclampsia, (vi) currently diagnosed gestational diabetes, (vii) currently diagnosed renal, liver, autoimmune, or bleeding disorders, (viii) currently diagnosed congestive heart failure, (ix) a history of significant gastrointestinal surgeries, such as bariatric surgery, cholecystectomy, or other surgical procedures affecting the stomach, liver, bile ducts and/or small intestine that may disrupt enterohepatic recycling of vitamin B12, (x) a condition requiring the use of the following medications: H2 blockers, proton pump inhibitors, or prokinetic agents, (xi) regular use of an over-the-counter, high dose vitamin B12 supplementation, (xii) cigarette smoking or tobacco chewing, (xiii) heavy alcohol use (>3 drinks per day, or >7 drinks per week), (xiv) current malaria infection, (xv) HIV/AIDS infection, and (xvi) known allergy to corn or hydroxyethyl starch (HES). The trial exclusion criteria for non-pregnant participants are the same, except severe anemia will be defined as hemoglobin <8 g/dL and the pregnancy-related criteria (multiple gestation, gestational diabetes, and preeclampsia) do not apply. Ethics approval and consent to participate The trial protocol was approved by George Washington University Institutional Review Board (Ref. No. NCR213648) on August 23, 2021, the Ifakara Health Institute Institutional Review Board (IHI/IRB/No: 47-2021) on November 9, 2021, the National Institute for Medical Research (NIMR) (Ref. No. NIMR/HQ/R.8a/Vol. IX/3963) on March 17, 2022, and the Tanzania Medicine and Medical Device Authority (TMDA) (Ref No. BD59/62/48/01) on July 5, 2022. Trained research staff will ask potential participants for written informed consent for trial enrollment as well as the use of their data and biological samples for future analyses. Who will take informed consent? We will identify potential study participants among pregnant participants attending antenatal clinics at the Bagamoyo District Hospital and sentinel dispensaries within the study area. Interested women will be invited to a sensitization meeting to learn more about the study. Those expressing interest will undergo pre-screening for eligibility. Any women who meet the initial inclusion criteria based on the pre-screening assessment will be invited to provide informed consent before proceeding to the screening procedures. Trained research staff will ask potential participants for written informed consent for trial enrollment as well as the use of their data and biological samples for future analyses. Additional consent provisions for collection and use of participant data and biological specimens In addition to participating in the study, study participants will be asked to provide consent for the collection and utilization of their biological specimens. This consent enables the staff to store blood samples for potential future research endeavors. If participants choose to withdraw their consent for the use of their blood samples in further research, they may simply inform any member of the study staff, prompting the removal or disposal of samples. Interventions Explanation for the choice of comparators We selected 2.6 µg, 10 µg, and 50 µg doses based on several factors including the established nutrient reference value, doses used in previous pregnancy trials, and known pharmacokinetic properties of B12. The RDA set by the United States and Canada for vitamin B12 is 2.6 µg/day 28 . In pregnant women, studies have used B12 doses ranging from 2.6 µg to 50 µg with no notable adverse events 3 , 29 , 30 . One study in Bangladesh found that although pregnant women received a daily multivitamin with 2.6 µg B12 across pregnancy, there were still high rates of B12 deficiency (<150 pmol/L) in the third trimester compared to their early pregnancy, non-supplemented baseline 28 . Established pharmacokinetic properties also influenced our dose selection. Vitamin B12 exhibits saturable dose-dependent absorption due to active processes involved in the absorption which limits bioavailability. On average, approximately 50% of a 1 µg dose and less than 5% of a 50 µg dose is absorbed 1 , 31 . Given the saturable absorption and subsequent refractory period, we hypothesized that dividing the doses for more frequent, lower amounts could potentially achieve higher serum B12 levels as compared to one single dose at higher doses. A pre-clinical study in mice reported that more frequent dosing through diet better resolved low B12 status as compared to single dosing, mimicking supplementation 30 . Thus, for this study the highest dose of B12 (50µg) will be evaluated as both Q24H dosing and Q12H dosing. Intervention description We will provide the participants with vitamin B12 supplementation in the form of pharmaceutical-grade cyanocobalamin (DSM Nutritional Products Ltd, Lot No. 2109451822), first dissolved in sterile water to prepare a working stock solution, and then added to juice for consumption by participants in a blinded manner. The participants will be instructed to consume the juice in a 5- to 10-minute period, followed by consumption of 100 mL of purified water. Participants will be provided with daily juices to consume, regardless of their assigned regimen, to facilitate blinding regarding the specific vitamin B12 regimen. For individuals assigned to a Q24H arm, they will receive plain juice with added sterile water in lieu of the second B12 solution. Thus the second daily supplement will contain no vitamin B12. Vitamin B12 doses will be provided to participants within 30 minutes following the morning meal (and evening meal for Q12H dosing) and observed directly by pharmacy staff. The intervention will occur in the context of a controlled feeding study where participants will be fed all food during their four-week inpatient stay from the on-site metabolic kitchen. All foods will be weighed on a gram scale with a 0.1g precision at all stages of food preparation, including raw ingredients, after cooking/preparation, and any returned/unconsumed food, to facilitate precise knowledge of the quantity prepared and consumed. A recipe database of culturally acceptable foods was developed and tested and integrated with the Tanzania Food Composition Tables to estimate nutritional contents 32 . Meals will be planned on an individual basis for patients, meeting estimated energy and protein needs, and providing 2.6 micrograms of food-based Vitamin B12 per day from animal products (no fortified products were provided). Energy requirements will be assessed using standard regression equations and adjusted upwards to meet the energy demands of pregnancy and to provide an additional 100–200 kilocalories per day to limit potential for weight loss given due to individual requirements being higher than average and potential for unconsumed foods. Weights will be monitored weekly to determine weight gain adequacy, assessed relative to the mean 0.4kg per week expected weight gain in pregnancy 33 . Insufficient weight gain will be assessed on an individual basis to determine likely etiology and adjust menus for the following week. Meal plans will be fixed for animal foods across participants to ensure similar Vitamin B-12 intakes and other animal food-based micronutrients, with energy and protein adjustments to meet individual requirements occurring through adjustment to planned quantities of low micronutrient starches. Standard operating procedures will be employed to ensure cleanliness of the metabolic kitchen and ensure safe food preparation and storage. Criteria for discontinuing or modifying allocated interventions The study investigators can request a participant to stop their participation in the study at any time in the case that they are concerned for the participants’ safety, or if the participant is unable or unwilling to follow study procedures. If an investigator terminates an individual’s participation in the study, the investigator will explain to the participant the reasons for the termination. Participants may withdraw from the study at any time without compromising the quality of care provided at the antenatal clinic. Strategies to improve adherence to interventions A strategy to improve adherence for our study intervention will involve administering the intervention under direct observation by the study pharmacist. Relevant concomitant care permitted or prohibited during the trial Participants will be provided with iron and folic acid supplements as well as sulfadoxine-pyrimethamine for malaria prophylaxis as per standard of care during the antenatal period. Provisions for post-trial care No provisions for ancillary and post-trial care. Outcomes The primary endpoints of the trial will be serum B12, holoTC, and the ratio of serum B12 to holoTC at four weeks. A steady state pharmacokinetic analysis will be used to evaluate the accumulation ratio (steady state B12 level/baseline B12 level) and relative bioavailability between the three doses of B12. The steady state B12 levels will be evaluated descriptively between the three different doses (2.6 µg, 10 µg and 50 µg), different baseline B12 status (sufficient and insufficient), pregnancy status (pregnant and non-pregnant), and other subject specific prognostic factors. Secondary outcomes will include: serum methylmalonic acid (MMA) at day 29; serum and urinary homocysteine at day 29; hematological response (hemoglobin, hematocrit, erythrocyte count, mean cell volume, reticulocyte number) at day 29. We will also assess the mean change from baseline to steady state B12 levels in pregnant participants for the three dose cohorts. The magnitude of difference (fold-change) in mean, baseline-adjusted steady state B12 levels between doses will be descriptively compared. Additionally, the proportion of participants who achieved or maintained sufficient B12 status will be assessed for each of the three dose cohorts. A dose with a higher fold difference (from 2.6 µg) and higher proportion of women having sufficient status will be identified as a priority B12 dose regimen. We will use metabolomics, proteomics, and genomics to identify novel biomarkers that can more robustly and sensitively reflect vitamin B12 status compared to conventional markers. Participant timeline Within three weeks after screening and enrollment, the trial will begin (Day 0) for the participants. Weeks 1 to 4 (Days 1 to 28) is the inpatient phase and day 29 is the discharge day ( Table 3 ). Exit assessments take place on Day 29, and a follow-up visit will be scheduled postpartum. During the inpatient phase, participants will receive their assigned B12 dose every day and biospecimens will be collected most days. On Saturdays, the participants can go home to visit their families for part of the day. Table 3. Dosing & Sampling Frequency. Dosing Sampling Frequency B12 Supplement Blood Sample Fecal Sample Urine Sample Screening X Enrollment Day 0 Inpatient Week 1 Day 1 Inpatient X X X X Day 2 Inpatient X X X Day 3 Inpatient X X Day 4 Inpatient X X Day 5 Inpatient X X Day 6 Home Visit X X Day 7 Inpatient X Week 2 Day 8 Inpatient X X X Day 9 Inpatient X Day 10 Inpatient X X Day 11 Inpatient X Day 12 Inpatient X X Day 13 Home Visit X Day 14 Inpatient X Week 3 Day 15 Inpatient X X X Day 16 Inpatient X Day 17 Inpatient X X Day 18 Inpatient X Day 19 Inpatient X X Day 20 Home Visit X Day 21 Inpatient X Week 4 Day 22 Inpatient X X X Day 23 Inpatient X X X Day 24 Inpatient X X Day 25 Inpatient X X Day 26 Inpatient X Day 27 Home Visit X Day 28 Inpatient X Week 5 Day 29 Discharge X X X X Sample size The main objectives of the Phase I dose escalation trial are to assess the pharmacokinetics (PK) of multiple ascending doses and to obtain information on the variability in serum B12 levels in pregnant participants after 4 weeks of supplementation. A total of 40 pregnant participants will be needed to precisely estimate the PK parameter (i.e., clearance) of B12 within 20% precision or the 95% confidence intervals within 60% and 140% of the geometric mean estimates of clearance at 90% power. The 40 pregnant participants will be stratified based on their baseline B12 status and assigned to the three B12 dose groups such that there are 5 participants per dose group per strata 31 . Additionally, 10 non-pregnant participants will be enrolled to serve as the reference group to understand potential differences in background B12 status in the Tanzanian population. The target sample size will therefore be 50 participants, including 40 pregnant and 10 non-pregnant participants. Recruitment Recruitment and enrollment are a multi-stage process ( Figure 1 ). We will recruit potential study participants among pregnant participants attending antenatal clinics at the Bagamoyo District Hospital and sentinel dispensaries in the study area. Information related to the study will be provided in different stages, starting with advertisements in the antenatal clinic waiting areas and presentations by nurses in charge of the clinics. Research Nurses will invite interested women with estimated gestational age <28 weeks, together with their spouses or partners, to a community sensitization meeting involving community health workers, study investigators, and members of the community advisory board (CAB). During the first meeting, the research team will explain the problem of malnutrition among pregnant participants and young children, current prevention strategies and their limitations with a focus on vitamin B12. We will discuss the need to have well-controlled feeding studies to guide future interventions of micronutrient deficiencies in pregnant participants, as well as a description of the objectives and design of the proposed clinical trial. Particular attention will be paid to study procedures like screening of eligible participants, adherence to protocol-specified diet, duration of in-facility observation, and timing of collecting samples for laboratory analysis. The meeting will be conducted in Swahili at designated community halls in the study area. Each couple attending this meeting will be provided with a copy of the participant information sheet (PIS). Figure 1. Recruitment, Screening, and Enrollment Process. Any interested participants will be invited to a second meeting; they will be listed in the pre-screening log and invited to the Kingani Clinical Trial Facility. The second session will provide a detailed explanation of the study, rationale, objectives, and methods. The potential study participants will be provided with an opportunity to ask questions and receive responses from the study investigators. Women who are still interested in participating will be pre-screened for eligibility. Any women who are likely eligible based on the pre-screening assessment will be invited to give informed consent before continuing the screening procedures. Consented women will then be invited to complete an ultrasound and give a blood sample for serum B12 assessment. They will be given appointments to start the trial when they reach the protocol defined gestational age at recruitment. We expect the whole process from sensitization meeting to confirming enrollment eligibility and consent will take 1–2 weeks. We note that there is potential selection bias in this recruitment method, and the study may be more likely to attract women who are not formally employed, who do not have other children at home, or who are single. However, such bias is unlikely to alter the biological mechanisms that we focus on in this study, specifically vitamin B12 pharmacokinetics, absorption, and metabolic parameters. Assignment of interventions: allocation Sequence generation The B12 pharmacokinetic study includes two strata: sufficient B12 status and insufficient B12 status. Within each strata, the study participants will be allocated to three B12 doses: 2.6 µg, 10 µg, and 50 µg in sequential, ascending order. Within each strata, dose 1 (2.6 µg) will be allocated to pregnant and non-pregnant participants. For the 50 µg dose only, randomization to Q12 or Q24 regimens will occur at enrollment. The study pharmacist will use a computer-generated list to randomly assign participants to the once or twice daily regimen. A list with numbers from 7777 through 8888 will be prepared according to a randomization sequence by the study statistician. The screening ID will be linked to the randomization ID by the pharmacist on site. The randomization code will have an “x” digit, the first digit indicating the study group and the following digits indicating the participant number within that group. In total, there will be 10 subgroups each with 5 participants. Concealment mechanism The dose assignment is maintained by the study statistician and pharmacist. The list is maintained in the locked pharmacy where only authorized personnel may enter. Implementation For the study implementation, the allocation sequence will be generated by the study statistician. Participants will be enrolled in the study by the study clinician, while assignment to the intervention will be conducted by the study pharmacist. Assignment of interventions: Blinding Who will be blinded The participants will be blinded to their dose level and the fact that the doses are provided in ascending order. Study staff responsible for data collection will also be blinded to the B12 dose regimen. The study pharmacist responsible for preparing the supplement and directly observing supplement administration, as well as study investigators, will not be blinded. Procedure for unblinding if needed Not applicable. Data collection and management Plans for assessment and collection of outcomes On the screening day, we will screen for infectious diseases using rapid diagnostic kits as currently used by the Government of Tanzania. These screening tests will include malaria, syphilis, hepatitis B, hepatitis C, and HIV. Additionally, we will assess participants for parasitic infections including soil-transmitted helminthiasis (STH) and schistosomiasis. On the screening day, enrollment day, and every day during the inpatient phase (days 1 to 29), we will conduct clinical assessments including measurements of weight and blood pressure. A micronutrients assessment panel will be done on the day 1, day 22, and day 29 and will include the following biomarkers: iron (serum ferritin, soluble transferrin receptor), vitamin A (retinol binding protein 4), and iodine (thyroglobulin). We will also assess biomarkers of inflammation including C-reactive Protein (CRP) and α-1-acid glycoprotein (AGP). We will assess proteomic, metabolomic, and metagenomics on days 1 and 29, as well as days 8, 21, and 22 for metabolomics. Throughout the trial, we will assess vitamin B12 status using multiple biomarkers including serum B12 and holoTC, which will be measured during the inpatient phase (screening day, days 1–6, day 8, day 10, day 12, days 14–15, day 17, day 19, days 21–29); and methylmalonic acid (MMA), total homocysteine (tHcy), Haptocorrin–holo, Haptocorrin–total that will be measured at: baseline (screening day), days 1–2, and subsequent Mondays (days 8, 15, 22, and 29). Plans to promote participant retention and complete follow-up Throughout the inpatient phase of the study, we will promote retention by ensuring participants are comfortable, well-fed, and adequately entertained. We will organize television and movie time, physical activities, and educational activities. To promote retention in the six weeks postpartum follow-up visit for pregnant participants, research staff will request the participants to inform the study team when they deliver the baby, or reach the endpoint of the pregnancy otherwise. Upon receiving such notification, the research staff will then schedule one final visit 42 days within the endpoint of the participant’s pregnancy. If the research staff do not hear from the participant two weeks after their estimated due date, the staff will follow up with them via phone call to inquire about the status of their pregnancy. Data management The trial data management team is responsible for overseeing the receiving, entering, cleaning, querying, analyzing and storing all data that accrues from the study. Trained study staff will input participant data into electronic Case Report Forms (CRFs) for specific components such as the screening form, enrollment data, baseline and demographic information, food frequency questionnaire, 24-hour dietary recall, ultrasound details, plasma volume measurement, clinical records, daily food records, daily B12 dosing records, daily maternal vital signs and GI complaints, postnatal follow-up documentation, adverse event log, protocol deviation log, withdrawal termination forms, and antenatal pregnancy health records. Laboratory sample requests for prescreening, screening, and routine daily testing, as well as the recording of all lab results data, will be initially documented using paper-based forms. Subsequently, this data will be entered into electronic databases for efficient management, sharing, and analysis purposes. All source documents and laboratory reports will be reviewed by the clinical team and signed by the study lead clinician and data manager who will ensure that they are accurate and complete. The electronic data capture system will be developed in REDCap, a secure and web-based application used for streamlined data collection and management in research studies. Data entry into the 21 CFR Part 11-compliant Electronic Data Capture system will be carried out by study staff. Clinical data will be entered directly from the source documents. Direct access to the study database will be granted to authorized representatives from implementing teams and regulatory authorities to permit trial-related monitoring, audits, and evaluation of the study safety, progress, and data validity. All source documents will be filed in participant files including: volunteer consent form, clinician’s medical notes, laboratory test results, and relevant correspondences. In the majority of cases, electronic CRF entries will be considered source data because it is the original recording of the information (i.e., there is no other written or electronic record of data). If participants fall ill and receive medical treatment, notes and investigational results will be considered as source documents and stored in participant files. All source documents will be stored safely in a locked filing cabinet where only authorized study investigators will have access. Only anonymized study data will be shared with third parties including study sponsors. Study documents will be retained for a minimum of 20 years after the end of the clinical trial. No records will be destroyed without the written consent of the PI, and it is the responsibility of the PI to inform the investigator when these documents no longer need to be retained. Confidentiality The investigators will maintain appropriate medical and research records for this trial in compliance with ICH E6 GCP and regulatory and institutional requirements for the protection of confidentiality of participants. The investigators will permit authorized representatives of regulatory agencies and the monitors to examine clinical records for the purposes of quality assurance reviews, audits and evaluation of the study safety and progress. The names of the participants and any other identifying detail will not be included in any trial data electronic file. On all trial-specific documents, other than the signed consent, the participant will be referred to by the trial Study ID number, and not by their identifying information. Plans for collection, laboratory evaluation and storage of biological specimens for genetic or molecular analysis in this trial/future use Whole blood samples will be collected throughout the duration of the study to assess B12 status, B12 biomarkers, micronutrient status, and inflammatory biomarkers. Table 3 outlines the sampling schedule. Specifically, for blood samples, one blood draw of 6 total mL (~0.4 tablespoons) will take place on the following days: screening day, days 4–6, 8, 10, 12, 15, 17, 19, 25, 29. Each 6 mL will be drawn into serum separator (4 mL SST) and plasma (2 mL K 2 -EDTA) blood collection tubes (Becton, Dickinson, and Co., Franklin Lakes, NJ). On days 2–3 and 23–24, two blood draws of 6 mL each will be taken. On day 1 and day 22, serum samples will be collected before supplement intake and at 14, 24, and 48 hours post-dose. These samples will be obtained by drawing 3 mL of whole blood into serum separator tubes. Additionally, on day 1 and day 22, plasma samples will be collected at pre-dose, 6, 14, and 24-hour intervals by drawing 3 mL of whole blood into K2-EDTA collection tubes. An additional 3 mL plasma sample will be collected on days 1 and 22, respectively, for plasma volume measurement. Plasma volume measurements will be conducted approximately 30 minutes before consumption of the morning meal and supplement. Participants should be fasted for >8 hours (no food) but continuing to drink water. Women will rest in a supine position on their left side for 10 minutes before insertion of an IV in an antecubital vein. They will rest for 5 minutes after IV insertion. After the rest period, a pre-injection blood draw will be conducted to collect whole blood in one 3 mL K 2 -EDTA blood collection tube. Thereafter, 170 mL of hydroxyethyl starch (HES) solution (HESPAN: 6% Hetastarch in 0.9% Sodium Chloride, B.Braund Medical Inc., L6511) will be injected through the IV catheter over 4 minutes followed by a flush with ~10 mL saline. A single post-HES injection blood sample of 3 mL in a K 2 -EDTA blood collection tube will be taken 10 minutes after completion of the HES injection. Twenty-four hour urine samples will also be collected 1 day per week on days 1, 8, 15, and 29. Participants will be given a sample collection jug and asked to use it for all urine voids. Samples will be mixed thoroughly before collecting 50 mL for storage. Fecal samples will be collected on Day 1–2, 22–23, and 29. All stool samples on these days will be collected and stored individually in 5 mL collection tubes. Upon collection, samples will be thoroughly mixed before aliquoting into storage vials. Samples will be immediately frozen at -80 degrees celsius. For pregnant participants, breast milk samples will be collected once at the 6 weeks postpartum visit. Samples will be collected by a pump and stored individually in 10 mL collection tubes and immediately frozen at -80 degrees celsius. Infant fecal samples will also be collected once at 6 weeks postpartum visit. All stool samples on these days will be collected and stored individually in 5 mL collection tubes. Samples will be thoroughly mixed before aliquoting into storage vials and immediately frozen at -80 degrees celsius. Blood, urine, and fecal samples will be processed and stored long term in the on-site laboratory. At specified times, a small portion of plasma and serum samples will be used to conduct infectious disease (Screening Day) and clinical testing (Screening Day, Day 1, 8, 15, 22, and 29). On Day 1 and 22, whole blood (from a K 2 -EDTA blood collection tube) will be used for a complete blood count. Whole blood will then be processed for plasma according to manufacturer instructions: blood collection tubes will be centrifuged at room temperature and 1000 to 1300 RCF for 10–15 minutes. Plasma will be aliquoted into ~500 uL aliquots for plasma volume measurement and storage at -80 degree celsius for later laboratory analysis as needed. Plasma volume assessment will occur on-site the same day of HES injection, or conducted from frozen plasma if same-day measurement is not possible. Glucose will be measured in the pre- and post-HES injection plasma samples using a hand-held glucometer. Laboratory procedures for processing the post-injection plasma have been described 34 . Samples are centrifuged and glucose is measured in the supernatant. Results will be entered into an equation to calculate plasma volume. Statistical methods Statistical methods for primary and secondary outcomes The primary focus of the analysis is to determine the most optimal dosage of vitamin B12 for pregnant participants with varying baseline levels of B12. Through descriptive analysis, we aim to identify the optimal dosage to be further examined in future research. For the primary analysis, steady state pharmacokinetic analysis will be used. The main objective of the analysis is to assess the steady levels of B12 for the different dose cohorts (2.6μg, 10μg and 50 μg) in pregnant participants. The data for the pharmacokinetic analysis will include the sparse B12 concentrations (dose: 2.6μg, 10μg and 50μg (both once daily and twice daily)) measured at multiple occasions over the 4-week time period. The pharmacokinetic analysis will involve two steps: (i) descriptive and graphical analysis (ii) steady state pharmacokinetic analysis to evaluate the accumulation ratio (steady state B12 level/baseline B12 level) and relative bioavailability between the three doses of B12. The steady state B12 levels will be evaluated descriptively between the three different doses (2.6μg, 10μg and 50μg), different baseline B12 status (sufficient and insufficient), pregnancy status (pregnant and non-pregnant) and other subject specific prognostic factors. To determine whether steady state of B12 has been achieved or not, individual and mean longitudinal graphs of pre-dose serum B12 levels over time across the three dose cohorts will be used. Presence of a flat profile over a period of time would indicate achievement of steady state. Additionally, the pre-dose B12 levels on three days during week 4 will be regressed over time and will be tested for the slope to be not different from zero. A mixed effects linear regression will be performed to assess the significance of slope. If the 95% confidence interval of slope would contain zero, then achievement of steady state will be made. As a secondary analysis, the following analyses will be conducted. Once the steady state is ascertained, from the mean change from baseline steady state B12 levels in pregnant participants for the three dose cohorts, magnitude of difference (fold-change) in mean change from baseline steady state B12 levels between doses will be descriptively compared. The mean change from baseline steady state B12 will be descriptively compared between the following subgroups namely by pregnancy status and other clinically relevant prognostic factors. Steady state levels will be utilized as surrogates for clearance to aid in selecting optimal doses for future trials. The relative bioavailability will be calculated as relF = (dose/mean steady state B12 for dose)/(dose = 2.6μg/mean steady state B12 for 2.6μg). Additionally, proportion of participants who achieved or maintained sufficient B12 status will be assessed for each of the three dose cohorts. A dose with a higher fold difference (from 2.6μg) and higher proportion of women on sufficient status will be identified as a priority B12 dose. To facilitate discovery of biomarkers associated with vitamin B12 intake, bioavailability, and metabolic outcomes in pregnancy, we plan to apply high throughput -omics approaches and associated bioinformatic pipelines to plasma samples derived from this study. Fecal samples procured throughout the trial (Day 1, 22, 29) will be subjected to shotgun metagenomic and metatranscriptomic sequencing, facilitating characterization of the functional profiles of present microbial communities in an unconstrained manner. High throughput metabolomics and proteomics will be facilitated by the Bill & Melinda Gates Foundation Global Health Platform Partners, Sapient Bioanalytics, LLC and Cedars-Sinai Precision Biomarker Laboratory, respectively. Microbial genome and transcriptome sequencing will be undertaken at the Broad Institute. Bioinformatic and statistical analysis of this data will be undertaken in the laboratory of the Dr. Ali Rahnavard, utilizing both existing and novel pipelines, to identify: (i) novel correlates of vitamin B12 intake and status; (ii) predictors of vitamin B12 bioavailability; (iii) predictors of the change in vitamin B12 status indicators and plasma volume expansion across pregnancy. Collectively, these multi-omic techniques will help to elucidate novel modifiers of nutrient metabolism during pregnancy and inform future investigations. Interim analyses The serum B12 results will be reviewed with the DSMB at the completion of each dose cohort. There are no stopping rules for the study. Methods for additional analyses (e.g. subgroup analyses) Not applicable. Methods in analysis to handle protocol non-adherence and any statistical methods to handle missing data While imputation techniques might not be suitable for our specific context, our analysis strategy is tailored to optimize available data. Participants with baseline B12 measurements and at least one subsequent B12 assessment will form the basis of our analysis cohort. In instances where B12 data are absent at particular time points for a participant, we will adopt a conservative approach by excluding those specific time points from the individual's analysis. This ensures that our analytical methods remain robust and reflective of the available data, thereby maintaining the integrity and reliability of our findings within the study framework. Plans to give access to the full protocol, participant level-data and statistical code The datasets generated from the trial may be made available from the corresponding author on reasonable request and approval from applicable Institutional Review Boards. Oversight and monitoring Composition of the coordinating centre and trial steering committee The international trial management team will meet weekly to review study progress, data quality, and any issues that arose during the past one week. Additionally, the implementing clinical team will meet every Monday in person and every Thursday virtually, that involves collaborators in the US. The controlled feeding kitchen team will meet weekly to review menus and discuss necessary modifications needed to meet participant requirements/requests. Composition of the data monitoring committee, its role and reporting structure The DSMB members will review primary outcome data after each dose cohort completes the inpatient phase of the trial. We will inform the DSMB of any severe adverse events within 48 hours. There are no specific stopping rules for this trial. Additionally the DSMB will review the protocol for scientific validity and any major concern prior to implementation, review study data to evaluate safety, quality of study conduct, and scientific integrity of the trial, and assess the performance of overall study operations. Additionally, a clinical trial monitor appointed by the sponsor, IRB committee and TMDA will intermittently monitor the conduct of the trial. Adverse event reporting and harms A serious adverse event (SAE) will be defined as any undesirable experience associated that is life-threatening or requires inpatient hospitalization. In this study, SAEs include death, life-threatening events (at substantial risk of dying at the time of the adverse event), inpatient hospitalization (initial or prolonged), and stillbirth. Any SAE will be reported to the Data and Safety Monitoring Board within 48 hours of reporting, as well as subsequently reported to the local safety monitor, and all ethics committees including those at The George Washington University, the Ifakara Health Institute (IHI), and the National Institute for Medical Research (NIMR). Frequency and plans for auditing trial conduct The study monitor will complete four clinical monitoring visits and a final close-out visit. Additionally, TMDA and IHI IRB are likely to conduct at least one oversight visit during the course of the trial. Plans for communicating important protocol amendments to relevant parties (e.g. trial participants, ethical committees) Any protocol modifications will be addressed and communicated to relevant parties (investigators, IRBs, trial participants, trial registries, TMDA) through written communication via email. Dissemination plans This study has potential benefits at the population level, and the results may also benefit study participants and local communities. Therefore, data will be aggregated and summarized for publications and presentations. During the study (after unblinding process) and upon completion of the trial, we will publish key research findings in peer-reviewed journals and scientific conference abstracts with suitable audiences. We will present selected results at conferences, research seminars, and meetings with a focus on nutrition in the global health context. We will also relate the findings back to the study participants and local communities using several approaches and guided by the community advisory board. For the study participants and local communities, we also plan to engage the study participants in a post-trial, voluntary focus group discussion. Through this focus group, we aim to understand their experiences as participants, gauge their understanding of the benefits and goals of the trial, and to glean feedback about how to improve future implementation of studies. After the focus group discussion, we will invite the local community members to join a meeting, during which we will share highlights of the study through science communication techniques. We will foster an interactive session to ensure that the key points are understood through a question and answer session at the end. We will also encourage community leaders to share feedback regarding how we may improve future studies to further benefit local communities. For local research partners, we will hold one research seminar at IHI to disseminate the results to the broader research community in Tanzania. Discussion This study is intended to inform our basic understanding of nutrient requirements in pregnancy. We will answer important questions about how vitamin B12 dose and status prior to supplementation affect saturable absorption and steady-state B12 status over the course of four weeks. We will provide preliminary data to answer the question about whether twice daily dosing, as compared to once daily dosing, can achieve a higher steady-state B12 status. We will also generate the first high quality pharmacokinetic data comparing pregnant and non-pregnant participants (with both sufficient and insufficient baseline vitamin B12 status) in the same population. To our knowledge, this will be the first controlled feeding study conducted in sub-Saharan Africa. There are several limitations to this study. First, we will not answer questions about how pharmacokinetic properties change over the course of pregnancy. We will not answer questions about how B12 status or vitamin B12 supplements impact pregnancy health or fetal/newborn health. We also cannot answer questions about the effect of vitamin B12 supplements and how pharmacokinetic properties compare between pregnant and non-pregnant people at doses above the RDA (2.6 µg) or how twice daily dosing compares to once daily dosing at doses below 50 µg. Trial status The protocol version of MM4MN B12 Dose Escalation Trial: Phase 1 is on Protocol version 3.7 dated January 16, 2023. Recruitment began May 29, 2023. The phase 1 trial enrollment was completed on December 18, 2023 and participant follow up and data collection is still ongoing. Ethics approval and consent to participate The trial protocol was approved by George Washington University Institutional Review Board (Ref. No. NCR213648) on August 23, 2021, the Ifakara Health Institute Institutional Review Board (IHI/IRB/No: 47-2021) on November 9, 2021, the National Institute for Medical Research (NIMR) (Ref. No. NIMR/HQ/R.8a/Vol. IX/3963) on March 17, 2022, and the Tanzania Medicine and Medical Device Authority (TMDA) (Ref No. BD59/62/48/01) on July 5, 2022. Trained research staff will ask potential participants for written informed consent for trial enrollment as well as the use of their data and biological samples for future analyses. Consent for publication Not applicable. Abbreviations AIDS AGP Acquired Immunodeficiency Syndrome α-1-acid glycoprotein BCTU BMI Bagamoyo Clinical Trial Unit Body Mass Index CAB CRF CRP Community Advisory Board Case Report Form C-reactive Protein dL DNA DRI DSMB deciliter Deoxyribonucleic Acid Dietary Reference Intake Data Safety and Monitoring Board EAR EDTA Estimated Average Requirement EthylenediamineTetraacetic Acid GCP GW g Good Clinical Practice George Washington University Grams HES HIV H2 Hydroxyethyl Starch Human Immunodeficiency Virus Hydrogen ICH ID IHI IRB IUGR IV International Council for Harmonization Identity Ifakara Health Institute Institutional Review Board Intrauterine Growth Restriction Intravenous kg Kilogram L LMIC LMP Liter Lower Middle-Income Countries Last Menstrual Period m mL MMA meter Milliliter Serum Methylmalonic Acid NIMR National Institute of Medical Research PI PIS PK pmol Principal Investigator Participant Information Sheet Pharmacokinetic Picomoles Q12H Q24H Twice Daily; Every 12 Hours Once Daily; Every 24 Hours RDA Recommended Dietary Allowance SAE SST STH Serious Adverse Event Serum Separator Tube Soil-transmitted helminthiasis tHcy Total Homocysteine µg μL Microgram Microliter Data availability Underlying data No data are associated with this article. Extended data Repository: SPIRIT checklist for ‘Single-blinded, stratified, dose ranging trial to assess pharmacokinetics and identify optimal dose of vitamin B12 in pregnancy in Tanzania. https://doi.org/10.17605/OSF.IO/GRVN4 23 Data are available under the terms of the Creative Commons Zero "No rights reserved" data waiver (CC0 1.0 Public domain dedication) Acknowledgements Authors’ contributions ERS, OL, KK, MB, AG, MG, HM, originated the concept for the trial and led development of the study design. ERS, OL, HM, HA, MB, SH, AA, KG, LAM, ADG, MG, KCK, ZL, SM, AR, VR developed the trial standard operating procedures and will oversee study procedures. ERS, OL, HM designed the data collection forms and data collection system. MG, BL, ERS contributed to the statistical analysis plan. ERS, VR, OL, HM wrote the initial draft of the protocol manuscript and all authors contributed to the manuscript and approved the final version. Faculty Opinions recommended References 1. Allen LH, Miller JW, de Groot L, et al. : Biomarkers of Nutrition for Development (BOND): vitamin B-12 review. J Nutr. 2018; 148 (suppl_ 4): 1995S–2027S. PubMed Abstract | Publisher Full Text | Free Full Text 2. Finkelstein JL, Layden AJ, Stover PJ: Vitamin B-12 and perinatal health. Adv Nutr. 2015; 6 (5): 552–563. PubMed Abstract | Publisher Full Text | Free Full Text 3. Bae S, West AA, Yan J, et al. : Vitamin B-12 status differs among pregnant, lactating, and control women with equivalent nutrient intakes. J Nutr. 2015; 145 (7): 1507–1514. PubMed Abstract | Publisher Full Text 4. Allen LH: Vitamin B 12 metabolism and status during pregnancy, lactation and infancy. Adv Exp Med Biol. 1994; 352 : 173–186. PubMed Abstract | Publisher Full Text 5. Behere RV, Deshmukh AS, Otiv S, et al. : Maternal vitamin B12 status during pregnancy and its association with outcomes of pregnancy and health of the offspring: a systematic review and implications for policy in India. Front Endocrinol (Lausanne). 2021; 12 : 619176. PubMed Abstract | Publisher Full Text | Free Full Text 6. Muthayya S, Kurpad AV, Duggan CP, et al. : Low maternal vitamin B 12 status is associated with intrauterine growth retardation in urban South Indians. Eur J Clin Nutr. 2006; 60 (6): 791–801. PubMed Abstract | Publisher Full Text 7. Murphy MM, Scott JM, Arija V, et al. : Maternal homocysteine before conception and throughout pregnancy predicts fetal homocysteine and birth weight. Clin Chem. 2004; 50 (8): 1406–1412. PubMed Abstract | Publisher Full Text 8. Black MM: Effects of vitamin B 12 and folate deficiency on brain development in children. Food Nutr Bull. 2008; 29 (2 Suppl): S126–S131. PubMed Abstract | Publisher Full Text | Free Full Text 9. Dror DK, Allen LH: Effect of vitamin B 12 deficiency on neurodevelopment in infants: current knowledge and possible mechanisms. Nutr Rev. 2008; 66 (5): 250–255. PubMed Abstract | Publisher Full Text 10. Jones KM, Ramirez-Zea M, Zuleta C, et al. : Prevalent vitamin B-12 deficiency in twelve-month-old Guatemalan infants is predicted by maternal B-12 deficiency and infant diet. J Nutr. 2007; 137 (5): 1307–1313. PubMed Abstract | Publisher Full Text 11. Honzik T, Adamovicova M, Smolka V, et al. : Clinical presentation and metabolic consequences in 40 breastfed infants with nutritional vitamin B12 deficiency--what have we learned? Eur J Paediatr Neurol. 2010; 14 (6): 488–495. PubMed Abstract | Publisher Full Text 12. Fernandes-Costa F, van Tonder S, Metz J: A sex difference in serum cobalamin and transcobalamin levels. Am J Clin Nutr. 1985; 41 (4): 784–786. PubMed Abstract | Publisher Full Text 13. Low-Beer TS, McCarthy CF, Austad WI, et al. : Serum vitamin B12 levels and vitamin B12 binding capacity in pregnant and non-pregnant Europeans and West Indians. Br Med J. 1968; 4 (5624): 160–161. PubMed Abstract | Publisher Full Text | Free Full Text 14. Metz J, Hart D, Harpending HC: Iron, folate, and vitamin B 12 nutrition in a hunter-gatherer people: a study of the Kung Bushmen. Am J Clin Nutr. 1971; 24 (2): 229–242. PubMed Abstract | Publisher Full Text 15. Smith ER, He S, Klatt KC, et al. : Limited data exist to inform our basic understanding of micronutrient requirements in pregnancy. Sci Adv. 2021; 7 (43): eabj8016. PubMed Abstract | Publisher Full Text | Free Full Text 16. Hellegers A, Okuda K, Nesbitt RE Jr, et al. : Vitamin B 12 absorption in pregnancy and in the newborn. Am J Clin Nutr. 1957; 5 (3): 327–331. PubMed Abstract | Publisher Full Text 17. Gernand AD, Schulze KJ, Stewart CP, et al. : Micronutrient deficiencies in pregnancy worldwide: health effects and prevention. Nat Rev Endocrinol. 2016; 12 (5): 274–289. PubMed Abstract | Publisher Full Text | Free Full Text 18. Murphy MM, Molloy AM, Ueland PM, et al. : Longitudinal study of the effect of pregnancy on maternal and fetal cobalamin status in healthy women and their offspring. J Nutr. 2007; 137 (8): 1863–1867. PubMed Abstract | Publisher Full Text 19. Morkbak AL, Hvas AM, Milman N, et al. : Holotranscobalamin remains unchanged during pregnancy. Longitudinal changes of cobalamins and their binding proteins during pregnancy and postpartum. Haematologica. 2007; 92 (12): 1711–1712. PubMed Abstract | Publisher Full Text 20. Abuyaman O, Andreasen BH, Kronborg C, et al. : The soluble receptor for vitamin B 12 uptake (sCD320) increases during pregnancy and occurs in higher concentration in urine than in serum. PLoS One. 2013; 8 (8): e73110. PubMed Abstract | Publisher Full Text | Free Full Text 21. Chan AW, Tetzlaff JM, Altman DG, et al. : SPIRIT 2013 statement: defining standard protocol items for clinical trials. Ann Intern Med. 2013; 158 (3): 200–207. PubMed Abstract | Publisher Full Text | Free Full Text 22. Chan AW, Tetzlaff JM, Gøtzsche PC, et al. : SPIRIT 2013 explanation and elaboration: guidance for protocols of clinical trials. BMJ. 2013; 346 : e7586. PubMed Abstract | Publisher Full Text | Free Full Text 23. Smith, ER, Reynolds V, Barberio M, et al. : Dose ranging trial of Vitamin B12 in pregnancy. OSF. 2024. http://www.doi.org/10.17605/OSF.IO/GRVN4 24. Bellows AL, Smith ER, Muhihi A, et al. : Micronutrient deficiencies among breastfeeding infants in Tanzania. Nutrients. 2017; 9 (11): 1258. PubMed Abstract | Publisher Full Text | Free Full Text 25. Minzi OMS, Marealle IA, Shekalaghe S, et al. : Comparison of bioavailability between the most available generic tablet formulation containing artemether and lumefantrine on the Tanzanian market and the innovator’s product. Malar J. 2013; 12 (1): 174. PubMed Abstract | Publisher Full Text | Free Full Text 26. Steiner-Monard V, Kamaka K, Karoui O, et al. : The candidate blood-stage malaria vaccine p27a induces a robust humoral response in a fast track to the field phase 1 trial in exposed and nonexposed volunteers. Clin Infect Dis. 2019; 68 (3): 466–474. PubMed Abstract | Publisher Full Text 27. Jongo SA, Church LWP, Mtoro AT, et al. : Safety and differential antibody and T-cell responses to the Plasmodium falciparum sporozoite malaria vaccine, PfSPZ Vaccine, by age in Tanzanian adults, adolescents, children, and infants. Am J Trop Med Hyg. 2019; 100 (6): 1433–1444. PubMed Abstract | Publisher Full Text | Free Full Text 28. Institute of medicine (US) Standing Committee on the scientific evaluation of dietary reference intakes and its panel on folate, other b vitamins, and choline. Dietary reference intakes for Thiamin, Riboflavin, Niacin, Vitamin B6, Folate, Vitamin B12, Pantothenic Acid, Biotin, and Choline. Washington (DC): National Academies Press (US), 2012. 29. Duggan C, Srinivasan K, Thomas T, et al. : Vitamin B-12 supplementation during pregnancy and early lactation increases maternal, breast milk, and infant measures of vitamin B-12 status. J Nutr. 2014; 144 (5): 758–764. PubMed Abstract | Publisher Full Text | Free Full Text 30. Schulze KJ, Mehra S, Shaikh S, et al. : Antenatal multiple micronutrient supplementation compared to iron-folic acid affects micronutrient status but does not eliminate deficiencies in a randomized controlled trial among pregnant women of rural Bangladesh. J Nutr. 2019; 149 (7): 1260–1270. PubMed Abstract | Publisher Full Text | Free Full Text 31. Chanarin I, Muir M, Hughes A, et al. : Evidence for intestinal origin of transcobalamin II during vitamin B12 absorption. Br Med J. 1978; 1 (6125): 1453–1455. PubMed Abstract | Publisher Full Text | Free Full Text 32. Tanzania food composition tables. The Nutrition Source, 2012. Reference Source 33. The American College of Obstetricians and Gynecologists: Weight gain during pregnancy. 2013. Reference Source 34. Vricella LK, Louis JM, Chien E, et al. : Blood volume determination in obese and normal-weight gravidas: the hydroxyethyl starch method. Am J Obstet Gynecol. 2015; 213 (3): 408.e1–6. PubMed Abstract | Publisher Full Text | Free Full Text Comments on this article Comments (0) Version 2 VERSION 2 PUBLISHED 04 Sep 2024 ADD YOUR COMMENT Comment Author details Author details 1 Ifakara Health Institute, Dar es Salaam, Tanzania 2 Department of Global Health, The Milken Institute School of Public Health, The George Washington University, Washington, District of Columbia, 20052, USA 3 Department of Exercise and Nutrition Science, The Milken Institute School of Public Health, The George Washington University, Washington, District of Columbia, 20052, USA 4 Department of Nutritional Sciences and Toxicology, University of California Berkeley, Berkeley, California, 94720, USA 5 Department of Clinical Pharmacology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania 6 Center for Translational Medicine, School of Pharmacy, University of Maryland Baltimore, Baltimore, Maryland, 21201, USA 7 Department of Obstetrics and Gynecology, Muhimbili University of Health and Allied Sciences, Dar es Salaam, Tanzania 8 Division of Maternal-Fetal Medicine, Department of Obstetrics & Gynecology, The George Washington University, Washington, District of Columbia, 20052, USA 9 Division of Maternal-Fetal Medicine, Department of Obstetrics and Gynecology, Inova Health System, Falls Church, VA, 22042, USA 10 Department of Nutritional Sciences, The Pennsylvania State University, University Park, Pennsylvania, 16802, USA 11 Ross and Carol Nese College of Nursing, The Pennsylvania State University - University Park Campus, University Park, Pennsylvania, 16802, USA 12 Computational Biology Institute, Departments of Biostatistics and Bioinformatics, The Milken Institute School of Public Health, The George Washington University, Washington, District of Columbia, 20052, USA Omar Lweno Roles: Conceptualization, Data Curation, Formal Analysis, Investigation, Methodology, Project Administration, Resources, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing Victoria S. Reynolds Roles: Project Administration, Resources, Writing – Original Draft Preparation, Writing – Review & Editing Matthew D. Barberio Roles: Conceptualization, Investigation, Methodology, Project Administration, Resources, Supervision, Validation, Visualization, Writing – Review & Editing Kevin C. Klatt Roles: Conceptualization, Investigation, Methodology, Project Administration, Resources, Supervision, Validation, Visualization, Writing – Review & Editing Sabina Mugusi Roles: Investigation, Project Administration, Resources, Supervision, Writing – Review & Editing Mathangi Gopalakrishnan Roles: Conceptualization, Formal Analysis, Methodology, Project Administration, Resources, Visualization, Writing – Review & Editing Zohra Lukmanji Roles: Project Administration, Resources, Supervision, Writing – Review & Editing Fadhlun M. Alwy Al-beity Roles: Project Administration, Supervision, Writing – Review & Editing Homa K. Ahmadzia Roles: Investigation, Project Administration, Resources, Supervision, Writing – Review & Editing Amrita Arcot Roles: Project Administration, Writing – Review & Editing Kelly Gallagher Roles: Project Administration, Writing – Review & Editing Leigh A. Martin Roles: Methodology, Project Administration, Writing – Review & Editing Ali Rahnavard Roles: Conceptualization, Methodology, Project Administration, Writing – Review & Editing Alison D. Gernand Roles: Conceptualization, Methodology, Project Administration, Resources, Supervision, Writing – Review & Editing Brooke Langevin Roles: Formal Analysis, Validation, Visualization, Writing – Review & Editing Honorati Masanja Roles: Conceptualization, Funding Acquisition, Investigation, Methodology, Project Administration, Software, Supervision, Writing – Original Draft Preparation, Writing – Review & Editing Emily R. Smith Roles: Conceptualization, Data Curation, Formal Analysis, Funding Acquisition, Investigation, Methodology, Project Administration, Resources, Software, Supervision, Validation, Visualization, Writing – Original Draft Preparation, Writing – Review & Editing Competing interests No competing interests were disclosed. Grant information This work was supported by the Gates Foundation [INV-016930].The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the protocol manuscript. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. Article Versions (2) version 2 Revised Published: 17 Sep 2025, 8:95 https://doi.org/10.12688/gatesopenres.15991.2 version 1 Published: 04 Sep 2024, 8:95 https://doi.org/10.12688/gatesopenres.15991.1 Copyright © 2024 Lweno O et al . This is an open access article distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. Download Export To Sciwheel Bibtex EndNote ProCite Ref. Manager (RIS) Sente metrics Views Downloads Gates Open Research - - PubMed Central info_outline Data from PMC are received and updated monthly. - - Citations open_in_new 0 open_in_new 0 open_in_new SEE MORE DETAILS CITE how to cite this article Lweno O, Reynolds VS, Barberio MD et al. Single-blinded, stratified, dose ranging trial to assess pharmacokinetics and identify optimal dose of vitamin B12 in pregnancy in Tanzania [version 1; peer review: 2 approved with reservations] . Gates Open Res 2024, 8 :95 ( https://doi.org/10.12688/gatesopenres.15991.1 ) NOTE: If applicable, it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS track receive updates on this article Track an article to receive email alerts on any updates to this article. TRACK THIS ARTICLE Share Open Peer Review Current Reviewer Status: ? Key to Reviewer Statuses VIEW HIDE Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Version 1 VERSION 1 PUBLISHED 04 Sep 2024 Views 0 Cite How to cite this report: Cochrane K. Reviewer Report For: Single-blinded, stratified, dose ranging trial to assess pharmacokinetics and identify optimal dose of vitamin B12 in pregnancy in Tanzania [version 1; peer review: 2 approved with reservations] . Gates Open Res 2024, 8 :95 ( https://doi.org/10.21956/gatesopenres.17350.r38162 ) The direct URL for this report is: https://gatesopenresearch.org/articles/8-95/v1#referee-response-38162 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 23 Oct 2024 Kelsey Cochrane , The University of Saskatchewan,, Saskatoon, Canada Approved with Reservations VIEWS 0 https://doi.org/10.21956/gatesopenres.17350.r38162 Overall In this study, 40 pregnant women and 10 non-pregnant women will be randomized 1 of 3 doses of vitamin B12 (2.6, 10 and 50) x 4 weeks. Randomization will be stratified by vitamin ... Continue reading READ ALL Overall In this study, 40 pregnant women and 10 non-pregnant women will be randomized 1 of 3 doses of vitamin B12 (2.6, 10 and 50) x 4 weeks. Randomization will be stratified by vitamin B12 status (“sufficient/insufficient”) Overall, the manuscript is clear. My main comment relates to assumptions that higher status means optimal status – perhaps more measured language should be used throughout to more accurately reflect outcomes expected for this study – e.g., that it will improve our understanding of dose-response to vitamin B12 during pregnancy, and how it varies as compared to a non-pregnant state. Unless status is shown be associated with a clinical outcome, its difficult to know clinical significance – while this study may explore associations with clinical outcomes, it likely isn’t powered to prove a causative association (but can be used to inform future studies). Abstract Overall the abstract is clear and well justified Would be helpful to add how often and when the primary endpoints (serum B12 markers) will be evaluated to the methods section. Is the primary goal to evaluate B12 status at a certain timepoint (at 4 weeks), change in status, or is it to generate a PK curve across multiple timepoints? Background Well written and well justified background. Good outline of available literature. Might be helpful to acknowledge the limitations of “sufficient” and “insufficient” cut-offs – that these are not established/may not be meaningful in pregnancy. This further supports the need for your study. Methods: I wonder if the language for objective #2 should be re-phrased – does increased status necessarily mean “improved” status? Is it possible that a decline in certain status indicators is normal in pregnancy? Something to consider re: the wording to “improve” status indicators. This also applies to the statistical methods section – can you really determine the “optimal” dose based on serum values (e.g., is highest necessarily optimal?) Why only single blinded? Is it possible to blind study investigators, or at minimum those doing statistical analyses/data interpretations? How was gestational age of 25-28 weeks determined? Re: exclusion criteria – what is considered “high dose” vitamin B12 supplementation? Do you expect that most participants will be routinely consuming a multiple micronutrient supplement, or is iron/folic acid supplementation only most common in this region? Does your sample size account for possible attrition? Have similar studies (e.g., inpatient, controlled feeding) been done in this region to get an idea of what attrition may look like? Suspect some individuals may not like the inpatient aspect, but I am not familiar with research norms in this region. Can a bit more detail on methods for breastmilk collection be provided – e.g., how much milk total is the study collecting – a full breast expression divided into 10 mL aliquots? What is the outcome to be evaluated in these specimens? Is the rationale for, and objectives of, the study clearly described? Yes Is the study design appropriate for the research question? Yes Are sufficient details of the methods provided to allow replication by others? Partly Are the datasets clearly presented in a useable and accessible format? Yes Competing Interests: No competing interests were disclosed. Reviewer Expertise: nutrition, B-vitamins, pregnancy, human milk I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Cochrane K. Reviewer Report For: Single-blinded, stratified, dose ranging trial to assess pharmacokinetics and identify optimal dose of vitamin B12 in pregnancy in Tanzania [version 1; peer review: 2 approved with reservations] . Gates Open Res 2024, 8 :95 ( https://doi.org/10.21956/gatesopenres.17350.r38162 ) The direct URL for this report is: https://gatesopenresearch.org/articles/8-95/v1#referee-response-38162 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Respond or Comment COMMENT ON THIS REPORT Views 0 Cite How to cite this report: Jiang Y. Reviewer Report For: Single-blinded, stratified, dose ranging trial to assess pharmacokinetics and identify optimal dose of vitamin B12 in pregnancy in Tanzania [version 1; peer review: 2 approved with reservations] . Gates Open Res 2024, 8 :95 ( https://doi.org/10.21956/gatesopenres.17350.r38160 ) The direct URL for this report is: https://gatesopenresearch.org/articles/8-95/v1#referee-response-38160 NOTE: it is important to ensure the information in square brackets after the title is included in this citation. Close Copy Citation Details Reviewer Report 11 Oct 2024 Yuan Jiang , Department of Neuroscience, Karolinska Institutet, Solna, Stockholm, Sweden Approved with Reservations VIEWS 0 https://doi.org/10.21956/gatesopenres.17350.r38160 The study protocol involves a single-blinded, stratified, dose-ranging trial in 40 pregnant women and 10 healthy controls, aiming to assess pharmacokinetics and identify the optimal dose of vitamin B12 during pregnancy in Tanzania. Participants are assigned to one of three ... Continue reading READ ALL The study protocol involves a single-blinded, stratified, dose-ranging trial in 40 pregnant women and 10 healthy controls, aiming to assess pharmacokinetics and identify the optimal dose of vitamin B12 during pregnancy in Tanzania. Participants are assigned to one of three doses (2.6, 10, and 50 µg) based on their baseline vitamin B12 status. Those receiving 50 µg are randomly assigned to receive this dose either once daily (Q24H) or twice daily (Q12H). Overall, the study is interesting and meaningful, but the authors need to provide further explanations in the following areas: For the 40 pregnant participants, please clarify why the gestational age of 25–28 weeks was chosen. One of the critical functions of B12 is the prevention of fetal neural tube malformations, which form around the 6th week of pregnancy. Therefore, the significance of vitamin B12 supplementation in early pregnancy might be even more important. The study includes a follow-up point at postpartum. However, it is unclear why adverse maternal and neonatal health outcomes are not included in this study. As the clinical-relevant vitamin B12 level is more important than the sufficient vitamin B12 status (the main outcome of this study), the measurement of adverse maternal and neonatal health outcomes might be more interesting. The concept of “sufficient status” for vitamin B12, which is a key outcome of this study, should be clearly defined and should be provided when the term is first mentioned, rather than in the last section of the statistical methods. Vitamin B12 is essential for many bodily functions. However, excessive amounts can have negative effects. Therefore, the potential side effects of achieving sufficient vitamin B12 status might be important to be recorded and analyzed. The authors mention that the sample size calculation is based on achieving a pharmacokinetic parameter (i.e., clearance) of B12 within 20% precision, or 95% confidence intervals within 60% and 140% of the geometric mean estimates of clearance at 90% power. The range of 60% to 140% seems too wide to be clinically meaningful. Please provide the reference for these values and describe the power calculation in detail. The drop-off rate should also be considered. The phrase “most days” in the description “participants will receive their assigned B12 dose every day and biospecimens will be collected most days” is vague and should be avoided. Please provide a more precise description. In the statistical methods section, the authors state that “to determine whether a steady state of B12 has been achieved, individual and mean longitudinal graphs of pre-dose serum B12 levels over time across the three dose cohorts will be used. The presence of a flat profile over a period of time would indicate achievement of steady state.” How will the study handle samples where a flat profile is not observed during the entire intervention period? Is the rationale for, and objectives of, the study clearly described? Yes Is the study design appropriate for the research question? Partly Are sufficient details of the methods provided to allow replication by others? Yes Are the datasets clearly presented in a useable and accessible format? Not applicable Competing Interests: No competing interests were disclosed. Reviewer Expertise: Convential epidemiology; genetic epidemiology; public health;randomized controlled trail I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. Close READ LESS CITE CITE HOW TO CITE THIS REPORT Jiang Y. Reviewer Report For: Single-blinded, stratified, dose ranging trial to assess pharmacokinetics and identify optimal dose of vitamin B12 in pregnancy in Tanzania [version 1; peer review: 2 approved with reservations] . Gates Open Res 2024, 8 :95 ( https://doi.org/10.21956/gatesopenres.17350.r38160 ) The direct URL for this report is: https://gatesopenresearch.org/articles/8-95/v1#referee-response-38160 NOTE: it is important to ensure the information in square brackets after the title is included in all citations of this article. COPY CITATION DETAILS Report a concern Respond or Comment COMMENT ON THIS REPORT Comments on this article Comments (0) Version 2 VERSION 2 PUBLISHED 04 Sep 2024 ADD YOUR COMMENT Comment keyboard_arrow_left keyboard_arrow_right Open Peer Review Reviewer Status info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Reviewer Reports Invited Reviewers 1 2 3 4 Version 2 (revision) 17 Sep 25 read read Version 1 04 Sep 24 read read Yuan Jiang , Karolinska Institutet, Solna, Sweden Kelsey Cochrane , The University of Saskatchewan,, Saskatoon, Canada Tor Strand , University of Bergen, Bergen, Norway Kristina Pentieva , Ulster University, Ulster, UK Comments on this article All Comments (0) Add a comment Sign up for content alerts Sign Up You are now signed up to receive this alert keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2026 Pentieva K. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 02 Jan 2026 | for Version 2 Kristina Pentieva , Ulster University, Ulster, UK 0 Views copyright © 2026 Pentieva K. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (0) Approved info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions The protocol outlines a single-blinded, dose-ranging trial of vitamin B12 supplementation in pregnant (gestational age 25–28 weeks) and non-pregnant Tanzanian women and it is aiming to generate data for the metabolic fate of B12 in pregnancy, to identify the supplemental dose required for optimization of B12 biomarkers as well as to identify novel biomarkers of vitamin B12 status relevant for pregnancy. The trial will be conducted under strictly controlled conditions in a Clinical Trial Unit where the participants will be kept inpatient for the duration of the supplementation. Based on baseline vitamin B12 status participants will be stratified (sufficient and insufficient) and depending on their reproductive state will be assigned for four weeks to the following B12 supplementation regimes: 1). Pregnant: sequentially to one of three doses: 2.6, 10, and 50 μg/day; 2). Non-pregnant: 2.6 μg/day. The study is carefully designed according to the rules for such trials and has the potential to generate valuable new data in relation to pharmacokinetics of vitamin B12 in pregnancy that would have implications for deriving of specific reference ranges of B12 biomarkers in pregnancy, correct diagnosis and management of B12 deficiency and for defining evidence-based requirements for B12 intake in pregnancy. Thus, the study should be of great interest considering that vitamin B12 deficiency is highly prevalent among pregnant women in low- and middle-income countries with serious consequences for fetal and maternal health, and that the currently available data in this research area are very limited. The protocol is very well written; however, in my view it would benefit if the following issues were addressed: 1. The text for the sample size estimation is very confusing. It is unclear what are the particular pharmacokinetic parameters that will be measured, what do you mean under 'clearance of B12' and what is the value of the 'geometric mean estimate of clearance'. Under the conditions of continuous vitamin B12 supplementation during the study (28 days) blood B12 concentrations would be expected to increase and maybe gradually to reach a steady state rather than going below the baseline or cleared from the circulation. Moreover, it is known that B12 is accumulated in the liver and due to its enterohepatic circulation, it is expected that B12 concentrations in plasma/serum will be maintained for some time even after the cessation of the supplementation. The reference provided for the sample size refers to drug pharmacokinetic studies in an acute setting where the maximum concentration and area under the curve are considered for the estimation but in the protocol these pharmacokinetic parameters have not been mentioned. In the ‘Statistical methods’ section is stated that ‘Steady state levels will be utilized as surrogates for clearance’ but there isn’t anything like this in the text for the sample size and how ‘steady state’ will be used as ‘clearance’ when these would go in different directions in the case of B12 supplementation. These issues need clarification. 2. Details should be provided for the laboratory methods that will be used for the assessment of vitamin B12 biomarkers: which laboratory will conduct the analysis, what are the variabilities of the methods and what will be the corresponding quality control. This information is required to support the reliability of the data that will be generated. 3. In the ‘Intervention description’ section is stated that ‘Vitamin B12 doses will be provided to participants within 30 minutes following the morning meal (and evening meal for Q12H dosing)’, however justification for this approach has not been provided. It is known that the absorption of Intrinsic Factor (IF)-B12 complex in the terminal ileum is limited to 1.5-2.5 μg per meal due to saturation of the apical surface receptors and there is a refractory period of a couple of hours with restricted IF-B12 uptake. Thus, B12 content of the meal provided 30 minutes before the supplemental dose may jeopardize the absorption of B12 from the supplement and care should be given in order this meal to contain a minimum amount of the total daily B12 intake from food. 4. Limited information is provided for the diet that participants will receive during the trial apart from the fact that it will be designed to contain the daily vitamin B12 requirements for pregnant women of 2.6 μg. Considering that this is a metabolic study, it would be a good practice the content of B12 in both total daily diet and supplement solution to be analytically verified in random samples throughout the different arms of the trial. 5. The protocol states that ‘The main objective of the analysis is to assess the steady levels of B12 for the different dose cohorts (2.6μg, 10μg and 50 μg) in pregnant participants’. However, the duration of the intervention is 4 weeks and there is a chance that for some of the biomarkers this will be not long enough to reach a steady level. Are you going to introduce a hierarchy for the importance/reliability of the biomarkers in that scenario? 6. There is a slight discrepancy in the indicated days for blood sampling on page 11 of the protocol in the subsections ‘Plans for assessment and collection of outcomes’ and ‘Plans for collection, laboratory evaluation and storage…’ that needs to be corrected. 7. The Abstract states that the outcome of the trial will not be able to compare Q12H and Q24H dosing at 50 µg/day. Probably this is an error as within the limitations in the protocol the text is different as it says that this problem will be confined to ‘at doses below 50 μg’. 8. There is some unclear text in the middle of the second paragraph, page 10 of the protocol that needs editing. Is the rationale for, and objectives of, the study clearly described? Yes Is the study design appropriate for the research question? Yes Are sufficient details of the methods provided to allow replication by others? Partly Are the datasets clearly presented in a useable and accessible format? Not applicable Competing Interests No competing interests were disclosed. Reviewer Expertise Micronutrients, B-vitamins, pregnant women, children, dietary recommendations, risk analysis I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard. reply Respond to this report Responses (0) Pentieva K. Peer Review Report For: Single-blinded, stratified, dose ranging trial to assess pharmacokinetics and identify optimal dose of vitamin B12 in pregnancy in Tanzania [version 1; peer review: 2 approved with reservations] . Gates Open Res 2024, 8 :95 ( https://doi.org/10.21956/gatesopenres.17759.r39958) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://gatesopenresearch.org/articles/8-95/v2#referee-response-39958 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2025 Strand T. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 24 Oct 2025 | for Version 2 Tor Strand , University of Bergen, Bergen, Norway 0 Views copyright © 2025 Strand T. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (0) Approved With Reservations info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions The introduction is comprehensive and well-written, providing a clear rationale for the study. However, it lacks references to recent large randomized controlled trials (RCTs) in pregnancy that could inform the expected response to the selected vitamin B12 doses—both in terms of average effect and variability in biomarker responses. The research question is highly relevant, and the proposed design is feasible. The study has the potential to generate valuable knowledge about the pharmacokinetics of cobalamin in pregnant women in a low-income setting. Stratifying participants by baseline serum cobalamin concentration makes sense, but the justification for the chosen cut-off values could be further elaborated. The study includes two strata (vitamin B12 sufficient and insufficient) within which participants will be assigned to one of three daily doses: 2.6 µg, 10 µg, or 50 µg. For the 50 µg dose, participants will be randomized to receive the supplement either once or twice daily. The doses will be tested sequentially, beginning with the lowest. Altogether, the study will include 10 distinct groups based on strata and randomization, with five participants per group. However, the terminology “subgroups” in the description (“In total, there will be 10 subgroups each with 5 participants”) is confusing and should be avoided or clarified. The different stratified intervention groups are not easy to understand from the text and I turned to the trial registry to further understand the design. I therefore believe that the 5 study arms could be described with more clarity in this protocol Differences in gastrointestinal function affecting the absorption of cobalamin may complicate the interpretation of pharmacokinetic. This increased variability will affect the interpretation of the results, particularly given the analytical approach (the way I understand it) particularly with regard to how the authors will interpret steady state (If the 95% confidence interval of slope would contain zero, then achievement of steady state will be made.) The inclusion of metabolomics, proteomics, and genomics to identify novel biomarkers of vitamin B12 status is innovative and potentially valuable. However, several methodological aspects require clarification: Please define the abbreviation “RCF” (or use g-force). Specify how biomarkers will be analyzed (e.g., immunological, microbiological, chromatographic, or combined approaches) and indicate where the analyses will be performed,. I suggest providing further detail on biomarker handling and analysis procedures, including sample storage and quality assurance The statistical analysis section is difficult to follow. This may partly reflect the reviewer’s limited background in pharmacokinetic methods; however, the text could still be made more accessible. The title suggests an RCT design with some degree of blinding, yet the analytical approach does not fully reflect this expectation. The rationale for stratification appears to be achieving balance across study groups, but it remains unclear how comparisons will be made within strata. The description of steady-state testing (“pre-dose B12 levels on three days during week 4 will be regressed over time…”) could be simplified or explained in more intuitive terms. The definition of steady state using mixed-effects regression and confidence intervals requires clearer justification. The sample size calculation is not fully accessible to me, and given the high biological variability of cobalamin and holoTC, the proposed sample size may be too small to meaningful describe differences (assuming that this is the purpose). Part of the analysis plan, particularly the comparison of fold-changes in mean steady-state B12 levels, is difficult to understand and should be rewritten for clarity. The section on interim analysis is also confusing to me. The statement that “The serum B12 results will be reviewed with the DSMB at the completion of each dose cohort. There are no stopping rules for the study.” does not describe an interim analysis in the conventional RCT sense. Rather, this appears to refer to ongoing safety and feasibility monitoring. In summary, this is a scientifically important and well-motivated study addressing a key evidence gap in pregnancy nutrition research. The design is feasible and thoughtfully planned. However, clarifications on biomarker analysis, statistical methods, stratification rationale, and interim procedures could be improved. Is this statement in the abstract correct? “This is the first controlled feeding study to be conducted in sub-Saharan Africa.”, if not, please reconsider. Table 2 presents the five study groups by stratum. I suggest simplifying this figure, as I initially struggled to understand it. I also suggest that you add information about the number in each bin (n=5). Is the rationale for, and objectives of, the study clearly described? Yes Is the study design appropriate for the research question? Yes Are sufficient details of the methods provided to allow replication by others? Partly Are the datasets clearly presented in a useable and accessible format? Not applicable Competing Interests No competing interests were disclosed. Reviewer Expertise Epidemiology and nutritoal clinical trials I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. reply Respond to this report Responses (0) Strand T. Peer Review Report For: Single-blinded, stratified, dose ranging trial to assess pharmacokinetics and identify optimal dose of vitamin B12 in pregnancy in Tanzania [version 1; peer review: 2 approved with reservations] . Gates Open Res 2024, 8 :95 ( https://doi.org/10.21956/gatesopenres.17759.r39860) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://gatesopenresearch.org/articles/8-95/v2#referee-response-39860 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2024 Cochrane K. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 23 Oct 2024 | for Version 1 Kelsey Cochrane , The University of Saskatchewan,, Saskatoon, Canada 0 Views copyright © 2024 Cochrane K. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (0) Approved With Reservations info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions Overall In this study, 40 pregnant women and 10 non-pregnant women will be randomized 1 of 3 doses of vitamin B12 (2.6, 10 and 50) x 4 weeks. Randomization will be stratified by vitamin B12 status (“sufficient/insufficient”) Overall, the manuscript is clear. My main comment relates to assumptions that higher status means optimal status – perhaps more measured language should be used throughout to more accurately reflect outcomes expected for this study – e.g., that it will improve our understanding of dose-response to vitamin B12 during pregnancy, and how it varies as compared to a non-pregnant state. Unless status is shown be associated with a clinical outcome, its difficult to know clinical significance – while this study may explore associations with clinical outcomes, it likely isn’t powered to prove a causative association (but can be used to inform future studies). Abstract Overall the abstract is clear and well justified Would be helpful to add how often and when the primary endpoints (serum B12 markers) will be evaluated to the methods section. Is the primary goal to evaluate B12 status at a certain timepoint (at 4 weeks), change in status, or is it to generate a PK curve across multiple timepoints? Background Well written and well justified background. Good outline of available literature. Might be helpful to acknowledge the limitations of “sufficient” and “insufficient” cut-offs – that these are not established/may not be meaningful in pregnancy. This further supports the need for your study. Methods: I wonder if the language for objective #2 should be re-phrased – does increased status necessarily mean “improved” status? Is it possible that a decline in certain status indicators is normal in pregnancy? Something to consider re: the wording to “improve” status indicators. This also applies to the statistical methods section – can you really determine the “optimal” dose based on serum values (e.g., is highest necessarily optimal?) Why only single blinded? Is it possible to blind study investigators, or at minimum those doing statistical analyses/data interpretations? How was gestational age of 25-28 weeks determined? Re: exclusion criteria – what is considered “high dose” vitamin B12 supplementation? Do you expect that most participants will be routinely consuming a multiple micronutrient supplement, or is iron/folic acid supplementation only most common in this region? Does your sample size account for possible attrition? Have similar studies (e.g., inpatient, controlled feeding) been done in this region to get an idea of what attrition may look like? Suspect some individuals may not like the inpatient aspect, but I am not familiar with research norms in this region. Can a bit more detail on methods for breastmilk collection be provided – e.g., how much milk total is the study collecting – a full breast expression divided into 10 mL aliquots? What is the outcome to be evaluated in these specimens? Is the rationale for, and objectives of, the study clearly described? Yes Is the study design appropriate for the research question? Yes Are sufficient details of the methods provided to allow replication by others? Partly Are the datasets clearly presented in a useable and accessible format? Yes Competing Interests No competing interests were disclosed. Reviewer Expertise nutrition, B-vitamins, pregnancy, human milk I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. reply Respond to this report Responses (0) Cochrane K. Peer Review Report For: Single-blinded, stratified, dose ranging trial to assess pharmacokinetics and identify optimal dose of vitamin B12 in pregnancy in Tanzania [version 1; peer review: 2 approved with reservations] . Gates Open Res 2024, 8 :95 ( https://doi.org/10.21956/gatesopenres.17350.r38162) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://gatesopenresearch.org/articles/8-95/v1#referee-response-38162 keyboard_arrow_left Back to all reports Reviewer Report 0 Views copyright © 2024 Jiang Y. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. 11 Oct 2024 | for Version 1 Yuan Jiang , Department of Neuroscience, Karolinska Institutet, Solna, Stockholm, Sweden 0 Views copyright © 2024 Jiang Y. This is an open access peer review report distributed under the terms of the Creative Commons Attribution License , which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. format_quote Cite this report speaker_notes Responses (0) Approved With Reservations info_outline Alongside their report, reviewers assign a status to the article: Approved The paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved Fundamental flaws in the paper seriously undermine the findings and conclusions The study protocol involves a single-blinded, stratified, dose-ranging trial in 40 pregnant women and 10 healthy controls, aiming to assess pharmacokinetics and identify the optimal dose of vitamin B12 during pregnancy in Tanzania. Participants are assigned to one of three doses (2.6, 10, and 50 µg) based on their baseline vitamin B12 status. Those receiving 50 µg are randomly assigned to receive this dose either once daily (Q24H) or twice daily (Q12H). Overall, the study is interesting and meaningful, but the authors need to provide further explanations in the following areas: For the 40 pregnant participants, please clarify why the gestational age of 25–28 weeks was chosen. One of the critical functions of B12 is the prevention of fetal neural tube malformations, which form around the 6th week of pregnancy. Therefore, the significance of vitamin B12 supplementation in early pregnancy might be even more important. The study includes a follow-up point at postpartum. However, it is unclear why adverse maternal and neonatal health outcomes are not included in this study. As the clinical-relevant vitamin B12 level is more important than the sufficient vitamin B12 status (the main outcome of this study), the measurement of adverse maternal and neonatal health outcomes might be more interesting. The concept of “sufficient status” for vitamin B12, which is a key outcome of this study, should be clearly defined and should be provided when the term is first mentioned, rather than in the last section of the statistical methods. Vitamin B12 is essential for many bodily functions. However, excessive amounts can have negative effects. Therefore, the potential side effects of achieving sufficient vitamin B12 status might be important to be recorded and analyzed. The authors mention that the sample size calculation is based on achieving a pharmacokinetic parameter (i.e., clearance) of B12 within 20% precision, or 95% confidence intervals within 60% and 140% of the geometric mean estimates of clearance at 90% power. The range of 60% to 140% seems too wide to be clinically meaningful. Please provide the reference for these values and describe the power calculation in detail. The drop-off rate should also be considered. The phrase “most days” in the description “participants will receive their assigned B12 dose every day and biospecimens will be collected most days” is vague and should be avoided. Please provide a more precise description. In the statistical methods section, the authors state that “to determine whether a steady state of B12 has been achieved, individual and mean longitudinal graphs of pre-dose serum B12 levels over time across the three dose cohorts will be used. The presence of a flat profile over a period of time would indicate achievement of steady state.” How will the study handle samples where a flat profile is not observed during the entire intervention period? Is the rationale for, and objectives of, the study clearly described? Yes Is the study design appropriate for the research question? Partly Are sufficient details of the methods provided to allow replication by others? Yes Are the datasets clearly presented in a useable and accessible format? Not applicable Competing Interests No competing interests were disclosed. Reviewer Expertise Convential epidemiology; genetic epidemiology; public health;randomized controlled trail I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above. reply Respond to this report Responses (0) Jiang Y. Peer Review Report For: Single-blinded, stratified, dose ranging trial to assess pharmacokinetics and identify optimal dose of vitamin B12 in pregnancy in Tanzania [version 1; peer review: 2 approved with reservations] . Gates Open Res 2024, 8 :95 ( https://doi.org/10.21956/gatesopenres.17350.r38160) NOTE: it is important to ensure the information in square brackets after the title is included in this citation. The direct URL for this report is: https://gatesopenresearch.org/articles/8-95/v1#referee-response-38160 Alongside their report, reviewers assign a status to the article: Approved - the paper is scientifically sound in its current form and only minor, if any, improvements are suggested Approved with reservations - A number of small changes, sometimes more significant revisions are required to address specific details and improve the papers academic merit. Not approved - fundamental flaws in the paper seriously undermine the findings and conclusions Adjust parameters to alter display View on desktop for interactive features Includes Interactive Elements View on desktop for interactive features Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Stay Updated Sign up for content alerts and receive a weekly or monthly email with all newly published articles Register with Gates Open Research Already registered? Sign in Not now, thanks close PLEASE NOTE If you are an AUTHOR of this article, please check that you signed in with the account associated with this article otherwise we cannot automatically identify your role as an author and your comment will be labelled as a “User Comment”. If you are a REVIEWER of this article, please check that you have signed in with the account associated with this article and then go to your account to submit your report, please do not post your review here. If you do not have access to your original account, please contact us . All commenters must hold a formal affiliation as per our Policies . The information that you give us will be displayed next to your comment. User comments must be in English, comprehensible and relevant to the article under discussion. We reserve the right to remove any comments that we consider to be inappropriate, offensive or otherwise in breach of the User Comment Terms and Conditions . Commenters must not use a comment for personal attacks. When criticisms of the article are based on unpublished data, the data should be made available. I accept the User Comment Terms and Conditions Please confirm that you accept the User Comment Terms and Conditions. Affiliation ✕ refresh Please enter your institution. Note: To add your institution or organisation, start typing the name and then select the correct name from the list. Where applicable, the name will appear in both the original language and in English. Do not paste in the name. If the name does not appear in the drop-down list, we will display the information you have entered. ✕ refresh Country/Region * USA UK Canada China France Germany Afghanistan Aland Islands Albania Algeria American Samoa Andorra Angola Anguilla Antarctica Antigua and Barbuda Argentina Armenia Aruba Australia Austria Azerbaijan Bahamas Bahrain Bangladesh Barbados Belarus Belgium Belize Benin Bermuda Bhutan Bolivia Bosnia and Herzegovina Botswana Bouvet Island Brazil British Indian Ocean Territory British Virgin Islands Brunei Bulgaria Burkina Faso Burundi Cambodia Cameroon Canada Cape Verde Cayman Islands Central African Republic Chad Chile China Christmas Island Cocos (Keeling) Islands Colombia Comoros Congo Cook Islands Costa Rica Cote d'Ivoire Croatia Cuba Cyprus Czech Republic Democratic Republic of the Congo Denmark Djibouti Dominica Dominican Republic Ecuador Egypt El Salvador Equatorial Guinea Eritrea Estonia Ethiopia Falkland Islands Faroe Islands Federated States of Micronesia Fiji Finland France French Guiana French Polynesia French Southern Territories Gabon Georgia Germany Ghana Gibraltar Greece Greenland Grenada Guadeloupe Guam Guatemala Guernsey Guinea Guinea-Bissau Guyana Haiti Heard Island and Mcdonald Islands Holy See (Vatican City State) Honduras Hong Kong Hungary Iceland India Indonesia Iran Iraq Ireland Israel Italy Jamaica Japan Jersey Jordan Kazakhstan Kenya Kiribati Kosovo (Serbia and Montenegro) Kuwait Kyrgyzstan Lao People's Democratic Republic Latvia Lebanon Lesotho Liberia Libya Liechtenstein Lithuania Luxembourg Macao Madagascar Malawi Malaysia Maldives Mali Malta Marshall Islands Martinique Mauritania Mauritius Mayotte Mexico Minor Outlying Islands of the United States Moldova Monaco Mongolia Montenegro Montserrat Morocco Mozambique Myanmar Namibia Nauru Nepal Netherlands Antilles New Caledonia New Zealand Nicaragua Niger Nigeria Niue Norfolk Island North Korea North Macedonia Northern Mariana Islands Norway Oman Pakistan Palau Palestinian Territory Panama Papua New Guinea Paraguay Peru Philippines Pitcairn Poland Portugal Puerto Rico Qatar Reunion Romania Russian Federation Rwanda Saint Helena Saint Kitts and Nevis Saint Lucia Saint Pierre and Miquelon Saint Vincent and the Grenadines Samoa San Marino Sao Tome and Principe Saudi Arabia Senegal Serbia Seychelles Sierra Leone Singapore Slovakia Slovenia Solomon Islands Somalia South Africa South Georgia and the South Sandwich Is South Korea South Sudan Spain Sri Lanka Sudan Suriname Svalbard and Jan Mayen Swaziland Sweden Switzerland Syria Taiwan Tajikistan Tanzania Thailand The Gambia The Netherlands Timor-Leste Togo Tokelau Tonga Trinidad and Tobago Tunisia Turkey Turkmenistan Turks and Caicos Islands Tuvalu UK USA Uganda Ukraine United Arab Emirates United States Virgin Islands Uruguay Uzbekistan Vanuatu Venezuela Vietnam Wallis and Futuna West Bank and Gaza Strip Western Sahara Yemen Zambia Zimbabwe Please select your country/region. You must enter a comment. Competing Interests Please disclose any competing interests that might be construed to influence your judgment of the article's or peer review report's validity or importance. Competing Interests Policy Provide sufficient details of any financial or non-financial competing interests to enable users to assess whether your comments might lead a reasonable person to question your impartiality. Consider the following examples, but note that this is not an exhaustive list: Examples of 'Non-Financial Competing Interests' Within the past 4 years, you have held joint grants, published or collaborated with any of the authors of the selected paper. You have a close personal relationship (e.g. parent, spouse, sibling, or domestic partner) with any of the authors. You are a close professional associate of any of the authors (e.g. scientific mentor, recent student). You work at the same institute as any of the authors. You hope/expect to benefit (e.g. favour or employment) as a result of your submission. You are an Editor for the journal in which the article is published. Examples of 'Financial Competing Interests' You expect to receive, or in the past 4 years have received, any of the following from any commercial organisation that may gain financially from your submission: a salary, fees, funding, reimbursements. You expect to receive, or in the past 4 years have received, shared grant support or other funding with any of the authors. You hold, or are currently applying for, any patents or significant stocks/shares relating to the subject matter of the paper you are commenting on. Please state your competing interests The comment has been saved. An error has occurred. Please try again. Cancel Post var lTitle = "Single-blinded, stratified, dose ranging...".replace("'", ''); var linkedInUrl = "http://www.linkedin.com/shareArticle?url=https://gatesopenresearch.org/articles/8-95/v1" + "&title=" + encodeURIComponent(lTitle) + "&summary=" + encodeURIComponent('Read the article by '); var deliciousUrl = "https://del.icio.us/post?url=https://gatesopenresearch.org/articles/8-95/v1&title=" + encodeURIComponent(lTitle); var redditUrl = "http://reddit.com/submit?url=https://gatesopenresearch.org/articles/8-95/v1" + "&title=" + encodeURIComponent(lTitle); linkedInUrl += encodeURIComponent('Lweno O et al.'); var offsetTop = /chrome/i.test( navigator.userAgent ) ? 4 : -10; var addthis_config = { ui_offset_top: offsetTop, services_compact : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_expanded : "facebook,twitter,www.linkedin.com,www.mendeley.com,reddit.com", services_custom : [ { name: "LinkedIn", url: linkedInUrl, icon:"/img/icon/at_linkedin.svg" }, { name: "Mendeley", url: "http://www.mendeley.com/import/?url=https://gatesopenresearch.org/articles/8-95/v1/mendeley", icon:"/img/icon/at_mendeley.svg" }, { name: "Reddit", url: redditUrl, icon:"/img/icon/at_reddit.svg" }, ] }; var addthis_share = { url: "https://gatesopenresearch.org/articles/8-95", templates : { twitter : "Single-blinded, stratified, dose ranging trial to assess pharmacokinetics.... Lweno O et al., published by " + "Gates Open Research" + ", https://gatesopenresearch.org/articles/8-95/v1" } }; if (typeof(addthis) != "undefined"){ addthis.addEventListener('addthis.ready', checkCount); addthis.addEventListener('addthis.menu.share', checkCount); } $(".f1r-shares-twitter").attr("href", "https://twitter.com/intent/tweet?text=" + addthis_share.templates.twitter); $(".f1r-shares-facebook").attr("href", "https://www.facebook.com/sharer/sharer.php?u=" + addthis_share.url); $(".f1r-shares-linkedin").attr("href", addthis_config.services_custom[0].url); $(".f1r-shares-reddit").attr("href", addthis_config.services_custom[2].url); $(".f1r-shares-mendelay").attr("href", addthis_config.services_custom[1].url); function checkCount(){ setTimeout(function(){ $(".addthis_button_expanded").each(function(){ var count = $(this).text(); if (count !== "" && count != "0") $(this).removeClass("is-hidden"); else $(this).addClass("is-hidden"); }); }, 1000); } close How to cite this report {{reportCitation}} Cancel Copy Citation Details $(function(){R.ui.buttonDropdowns('.dropdown-for-downloads');}); $(function(){R.ui.toolbarDropdowns('.toolbar-dropdown-for-downloads');}); $.get("/articles/acj/15991/17350") new F1000.Clipboard(); new F1000.ThesaurusTermsDisplay("articles", "article", "17350"); $(document).ready(function() { $( "#frame1" ).on('load', function() { var mydiv = $(this).contents().find("div"); var h = mydiv.height(); console.log(h) }); var tooltipLivingFigure = jQuery(".interactive-living-figure-label .icon-more-info"), titleLivingFigure = tooltipLivingFigure.attr("title"); tooltipLivingFigure.simpletip({ fixed: true, position: ["-115", "30"], baseClass: 'small-tooltip', content:titleLivingFigure + " " }); tooltipLivingFigure.removeAttr("title"); $("body").on("click", ".cite-living-figure", function(e) { e.preventDefault(); var ref = $(this).attr("data-ref"); $(this).closest(".living-figure-list-container").find("#" + ref).fadeIn(200); }); $("body").on("click", ".close-cite-living-figure", function(e) { e.preventDefault(); $(this).closest(".popup-window-wrapper").fadeOut(200); }); $(document).on("mouseup", function(e) { var metricsContainer = $(".article-metrics-popover-wrapper"); if (!metricsContainer.is(e.target) && metricsContainer.has(e.target).length === 0) { $(".article-metrics-close-button").click(); } }); var articleId = $('#articleId').val(); if($("#main-article-count-box").attachArticleMetrics) { $("#main-article-count-box").attachArticleMetrics(articleId, { articleMetricsView: true }); } }); var figshareWidget = $(".new_figshare_widget"); if (figshareWidget.length > 0) { window.figshare.load("f1000", function(Widget) { // Select a tag/tags defined in your page. In this tag we will place the widget. _.map(figshareWidget, function(el){ var widget = new Widget({ articleId: $(el).attr("figshare_articleId") //height:300 // this is the height of the viewer part. [Default: 550] }); widget.initialize(); // initialize the widget widget.mount(el); // mount it in a tag that's on your page // this will save the widget on the global scope for later use from // your JS scripts. This line is optional. //window.widget = widget; }); }); } close Error Close Add Reset F1000.MICROSERVICES.AFFILIATION = ''; $(document).ready(function () { $('.js-affiliations-form').each((index, form) => { new AffiliationForm({ formId: form.id, institutionErrorSelector: '.comment-enter-institution', departmentErrorSelector: '.comment-enter-department', placeSelector: '.js-add-comment-place', stateSelector: '.js-add-comment-state', zipCodeSelector: '.js-add-comment-zipcode', countrySelector: '.js-add-comment-country', countryErrorSelector: '.comment-enter-country', }); }); }); $(document).ready(function () { var reportIds = { "39946": 0, "39947": 0, "39948": 0, "38156": 0, "39949": 0, "38157": 0, "39950": 0, "38158": 0, "39951": 0, "38159": 0, "39952": 0, "38160": 15, "39953": 0, "38161": 0, "39954": 0, "38162": 15, "39955": 0, "38163": 0, "39956": 0, "38164": 0, "39957": 0, "38165": 0, "39958": 7, "39959": 0, "39960": 0, "39961": 0, "39962": 0, "39963": 0, "39964": 0, "39965": 0, "39853": 0, "39854": 0, "39855": 0, "39856": 0, "39857": 0, "39858": 0, "39859": 0, "39860": 12, "39861": 0, "39862": 0, "38070": 0, "39863": 0, "38071": 0, "39864": 0, "38072": 0, "38073": 0, "38074": 0, "38075": 0, "38076": 0, "38077": 0, "38078": 0, "38079": 0, "37964": 0, "37965": 0, "37966": 0, "37967": 0, "37968": 0, "37969": 0, "37970": 0, "37971": 0, "37972": 0, "37973": 0, "39927": 0, "39928": 0, "39929": 0, "39930": 0, "39931": 0, "39932": 0, "39933": 0, "39934": 0, "39935": 0, }; $(".referee-response-container,.js-referee-report").each(function(index, el) { var reportId = $(el).attr("data-reportid"), reportCount = reportIds[reportId] || 0; $(el).find(".comments-count-container,.js-referee-report-views").html(reportCount); }); var uuidInput = $("#article_uuid"), oldUUId = uuidInput.val(), newUUId = "65fbdf1c-2404-4180-9750-c34bdd1ef6aa"; uuidInput.val(newUUId); $("a[href*='article_uuid=']").each(function(index, el) { var newHref = $(el).attr("href").replace(oldUUId, newUUId); $(el).attr("href", newHref); }); }); Are you a Gates-funded researcher? If you are a previous or current Gates grant holder, sign up for information about developments, publishing and publications from Gates Open Research. First Name * You must provide your first name Last Name * You must provide your last name Email * You must provide a valid email address Institution You must provide an institution. Submit Thank you! We'll keep you updated on any major new updates to Gates Open Research Gates Open Research Browse Gateways How to Publish About Contact Legal For Developers Cookie Notice Privacy Notice RSS Submit via VeriXiv © F1000 Research Limited and its licensors ISSN 2572-4754 var F1000platform = new F1000.Platform({ name: "gates", displayName: "Gates Open Research", hostName: "gatesopenresearch.org", id: "3", editorialEmail: "[email protected]", infoEmail: "[email protected]", usePmcStats: true }); Sign In Remember me Forgotten your password? Sign In Cancel Email or password not correct. Please try again Please wait... $(function(){ // Note: All the setup needs to run against a name attribute and *not* the id due the clonish // nature of facebox... $("a[id=googleSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("GOOGLE"); $("form[id=oAuthForm]").submit(); }); $("a[id=facebookSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("FACEBOOK"); $("form[id=oAuthForm]").submit(); }); $("a[id=orcidSignInButton]").click(function(event){ event.preventDefault(); $("input[id=oAuthSystem]").val("ORCID"); $("form[id=oAuthForm]").submit(); }); }); If you've forgotten your password, please enter your email address below and we'll send you instructions on how to reset your password. The email address should be the one you originally registered with F1000. Email address not valid, please try again You registered with F1000 via Google, so we cannot reset your password. To sign in, please click here . If you still need help with your Google account password, please click here . You registered with F1000 via Facebook, so we cannot reset your password. To sign in, please click here . If you still need help with your Facebook account password, please click here . Code not correct, please try again Reset password Cancel Email us for further assistance. Server error, please try again. If your email address is registered with us, we will email you instructions to reset your password. If you think you should have received this email but it has not arrived, please check your spam filters and/or contact for further assistance. Please wait... Register $(document).ready(function () { signIn.createSignInAsRow($("#sign-in-form-gfb-popup")); $(".target-field").each(function () { var uris = $(this).val().split("/"); if (uris.pop() === "login") { $(this).val(uris.toString().replace(",","/")); } }); });